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Case vignette
At her quarterly visit to the outpatient clinic, a 37-year-old mother of two children with type 
1 diabetes mellitus reports that a severe hypoglycaemic incident has occurred a few weeks 
earlier. Her five year-old daughter had found her unconsciously on the floor and had called 
the neighbours, one of whom was able to administer glucagon intramuscularly, after which 
she regained consciousness. She has a 33-year history of diabetes without microvascular 
complications and is treated with short-acting insulin analogues before meals and one 
injection of basal insulin at bedtime. Glycaemic control has always been reasonable (yet not 
optimal) with HbA1c values ranging from 55-69 mmol/mol. Home blood glucose measurements 
disclose many low values, the majority of which – the patient admits – are not accompanied 
by hypoglycaemic symptoms. Family members often recognize her hypoglycaemic 
symptoms before she is aware of them herself. When she does, the presenting symptoms are 
usually loss of concentration or diminishing visual acuity rather than sweating, palpitations 
or feeling hungry that used to be presenting symptoms many years earlier. She feels insecure, 
especially when she is alone with her children. She likes to know why hypoglycaemic events 
occur so often, why she does not perceive her symptoms any more, and what has led to 
the severe episode. She also asks whether hypoglycaemic episodes are harmful, if they lead 
to complications similar to those associated with hyperglycaemia, and what she can do to 
avoid these events from happening. 
Type 1 diabetes
Diabetes mellitus is characterized by chronic elevation of blood glucose levels 
(hyperglycaemia) caused by insulin deficiency that can either be absolute (type 1 diabetes) 
or relative when accompanied by insulin resistance (type 2 diabetes). Hyperglycaemia 
causes chronic complications, i.e. microvascular complications leading to blindness, kidney 
failure, peripheral and autonomic neuropathy, and macrovascular complications leading 
to peripheral, coronary or cerebral vascular disease. These chronic complications lead to 
a large disease burden and reduced life expectancy. Diabetes mellitus is a highly prevalent 
global disease. Worldwide, an estimated 415 million people have diabetes mellitus (1), up 
to half of whom are not diagnosed yet, especially in low-income countries. A minority of 
people with diabetes mellitus is diagnosed with type 1 diabetes. In the Netherlands, about 1 
million people have been diagnosed with diabetes mellitus, 10% of whom suffer from type 
1 diabetes (2). 
In type 1 diabetes, an autoimmune process that selectively destroys the insulin producing 
beta-cells of the pancreas causes an absolute insulin deficiency. When left untreated, type 
1 diabetes leads to uncontrolled hyperglycaemia, severe dehydration, ketoacidosis and – 
ultimately – death. Insulin therapy is life saving for people with type 1 diabetes. In addition, 
tight glycaemic control has been shown to reduce the risk of micro- and macrovascular 
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complications and to improve survival (3, 4). Current insulin therapy consists of insulin 
administration either by multiple daily injections or by continuous subcutaneous insulin 
infusion (CSII) using a pump (5). Ever since the Diabetes Control and Complications Trial 
(DCCT) (3), it has become standard practice to administer insulin according to a basal-bolus 
regimen, in an attempt to match the physiology of daily fluctuating endogenous insulin 
requirements as closely as possible. However, despite modern insulin and insulin delivery 
devices, it has been proven impossible to completely eliminate hyper- and hypoglycaemia. 
Hypoglycaemia
Clinical hypoglycaemia rarely occurs in healthy human beings, but it is a fact of life for people 
with type 1 diabetes mellitus and (advanced) insulin-treated type 2 diabetes. Consequently, 
iatrogenic hypoglycaemia remains the principal barrier to obtaining true glycaemic control, 
i.e. blood glucose values that remain within normoglycaemic limits for an indefinite period 
of time (6). Thus, it could be posited that microvascular and macrovascular complications of 
diabetes associated with chronic hyperglycaemia are to a certain extent the consequence of 
(the fear for) hypoglycaemia. Hypoglycaemia is feared by many patients, not only because 
of the associated physical discomfort, but also because of the risk of cognitive function 
deterioration that may lead to loss of personal control and adequate conscious behaviour, 
and eventually to coma, seizures or worse. Up to 10 % of deaths among people with type 
1 diabetes under the age of 50 has been attributed to hypoglycaemia (7-9).  Iatrogenic 
hypoglycaemia has been described ever since the introduction of insulin (10), and especially 
those patients attempting to optimize glycaemic control may suffer multiple episodes a 
week and – on average – one severe episode requiring third-party assistance per year (11, 
12). The DCCT has reported an inverse relationship between HbA1c and the incidence of 
severe hypoglycaemia (3), but this association is less robust than initially thought. Indeed 
and perhaps somewhat surprisingly, hypoglycaemia, including severe events, may also be 
common among patients with poorly controlled diabetes, especially children (13, 14).
Role of therapeutic insulin in risk for hypoglycaemia 
When discussing potential causes of a hypoglycaemic event with a patient with type 1 
diabetes like the patient in the case vignette, it is common to search primarily for the 
classical risk factors for hypoglycaemia such as missed meals, excess insulin administration, 
alcohol consumption, and physical activity or sport. However appropriate this may be, 
many instances of hypoglycaemia are not the result of patient mistakes, but relate to 
imperfections in therapeutic insulin as opposed to endogenous insulin. In the nondiabetic 
individual, endogenous insulin release is instantaneous and tailor-made to the amount of 
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carbohydrates that enter the circulation or to any other increase in the blood glucose level. 
Moreover, aft er its release by the pancreatic beta-cell, insulin first reaches the liver via the 
portal vein to promote glucose uptake, to stimulate hepatic glycogen synthesis and to inhibit 
hepatic gluconeogenesis. Within the liver, insulin is extracted up to 80% (15, 16), so that only 
a fraction of the insulin released reaches the periphery to stimulate skeletal muscle glucose 
disposal and to inhibit lipolysis in adipose tissue. With therapeutic insulin, insulin levels 
cannot be regulated and do not decrease until the subcutaneous depot is depleted, even 
though the plasma glucose level may have started to fall (too low). In addition, insulin injected 
subcutaneously enters the circulation much slower and follows the reverse route, so that 
elevated plasma insulin levels persist considerably longer. Variations in insulin absorption 
may explain why a dose of insulin suff icient to maintain normoglycaemia at one time may be 
too high at other times. All these factors may lead to inappropriate hyperinsulinemia, hence 
creating a risk for hypoglycaemia (17). 
Normal glucose counterregulation 
Figure 1 Schematic presentation of physiological glycaemic threshold values for counterregulatory responses to 
and psysiological consequences of insulin induced hypoglycaemia
In the nondiabetic individual, declining blood glucose levels trigger a characteristic and 
hierarchically organized sequence of responses (figure 1)(18, 19).
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First and foremost, insulin secretion is suppressed when blood glucose levels fall within the 
physiological range (below ~4.6 mmol/l). The resultant reduction in peripheral glucose uptake 
and increase in hepatic glucose production usually terminates the decline in blood glucose 
and prevents true hypoglycaemia almost without exception. In addition, the fall in intra-
islet insulin appears to have a signalling role for the glucagon response to hypoglycaemia 
by alleviating its suppressive effect on pancreatic alpha-cells, thus permitting glucagon 
release (20, 21). The release of both glucagon and adrenaline is triggered when plasma 
glucose values fall below ~3.9 mmol/l (18, 19). These hormones promote hepatic glucose 
production by stimulation of glycogenolysis and gluconeogenesis. In addition, adrenaline 
inhibits peripheral glucose uptake and contributes to mobilisation of gluconeogenic 
precursors (e.g. through lipolysis). The adrenaline response is normally not critical, provided 
the glucagon response is intact. Cortisol and growth hormone are released in response to 
prolonged hypoglycaemia, but have low significance for acute glucose counterregulation. 
Plasma glucose values below 3.5 mmol/l trigger central nervous system (CNS)-mediated 
onset of autonomic warning symptoms such as hunger, sweating and palpitations (18, 19, 
22, 23), all of which are fundamental to allow subjective awareness of hypoglycaemia. These 
symptoms are aimed to provoke eating behaviour and can be seen as a last resort before 
neuroglycopenia develops and cognitive function declines, both of which reflect CNS glucose 
deprivation (table 1). 
Table 1. Symptoms of hypoglycaemia
The glucose levels at which these counterregulatory responses to hypoglycaemia occur, also 
referred to as glycaemic thresholds, are reproducible in healthy subjects (24-26), yet can be 
altered to higher glucose levels following chronic hyperglycaemia (27) or to lower glucose 
levels following repeated hypoglycaemia (13, 24, 25). The magnitude of counterregulatory 
function as a whole tends to decrease with age (28) and is more prominent in men than in 
(premenopausal) women (29).
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Glucose counterregulation in diabetes 
Glucose counterregulation in patients with type 1 diabetes is typically impaired. The loss 
of insulin-producing capacity disrupts the first-line defence against falling blood glucose 
levels and the consequent lack of paracrine control of the pancreatic alpha-cell precludes 
an adequate glucagon response. Therefore, hypoglycaemia usually fails to trigger glucagon 
responses in type 1 diabetes within years after diagnosis, when residual beta-cell function has 
eventually disappeared (30, 31). The absence of an increase in glucagon secretion in response 
to hypoglycaemia is not fully elucidated. Beta-cell failure is most likely responsible for the 
loss in glucagon response upon hypoglycaemia since the secretory response to administered 
amino acids is preserved in patients with failing glucagon response to hypoglycaemia (21, 
31-40). There is insufficient evidence that excessive delta-cell produced somatostatin release 
during hypoglycaemia suppresses glucagon release (41-43). Data support the conclusion 
that an absolute endogenous insulin deficiency causes a loss of an increase in alpha cell 
secretion to hypoglycaemia. 
When glucagon responses to hypoglycaemia are deficient, adrenaline and autonomic 
warning symptoms become critical for the integrity of glucose counterregulation. Iatrogenic 
hypoglycaemia, however, attenuates the magnitude of adrenaline and autonomic symptom 
responses to a subsequent hypoglycaemic episode, shifts the glycaemic threshold for these 
responses to lower glucose levels (24, 44, 45), impairs hypoglycaemic perceptibility clinically 
(46), and reduces beta-adrenergic sensitivity (47-51). Any hypoglycaemia, whether mild (25), 
asymptomatic, nocturnal (52, 53), or brief (26, 54, 55), can provoke this process of habituation 
to hypoglycaemia. Consequently, a downward vicious cycle of worsening counterregulation 
and recurrent hypoglycaemia may progressively impair hormonal responses to and 
symptomatic awareness of hypoglycaemia. The loss of symptoms is functional rather than 
structural, as meticulous avoidance of hypoglycaemia is the key to escape from this vicious 
cycle and to restore awareness of hypoglycaemia (56-58).
Impaired awareness of hypoglycaemia
When habituation to hypoglycaemia progresses, patients with type 1 diabetes may eventually 
lose the ability to timely recognize hypoglycaemic events in all or most instances, a clinical 
condition known as impaired awareness of hypoglycaemia (IAH). This condition is defined as 
the onset of neuroglycopenia before the appearance of autonomic warning symptoms, and 
characterized clinically by the inability to detect hypoglycaemia on the basis of (in particular 
autonomic) symptoms (table 1). Various cross-sectional studies across Europe and the US 
performed over the past 20 years have revealed that IAH affects approximately 20-30% of 
patients with type 1 diabetes (59-63). Patients with impaired awareness of hypoglycaemia 
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are less able to manifest an adequate behavioural response to avert hypoglycaemia and 
are at six-fold higher risk of severe, disabling hypoglycaemia (e.g. complicated by coma or 
seizures) that requires external assistance (59). IAH usually coincides with defects in hormonal 
counterregulation, the combination of which is sometimes referred to as hypoglycaemia-
associated autonomic failure (HAAF) (figure 2) (64-67). 
Figure 2: Hypoglycaemia associated autonomic failure
IAH is not the result of neuropathy. Although diabetic autonomic neuropathy shares many of 
the symptomatic defects with impaired awareness of hypoglycaemia (68-70), most patients 
with IAH have no signs of autonomic neuropathy or microangiopathy. In cross-sectional 
studies, classical diabetic autonomic neuropathy was not associated to counterregulatory 
failure or hypoglycaemic incidence (71, 72). 
Pathogenesis of counterregulatory failure 
The brain probably plays a pivotal role in the development of impaired awareness of 
hypoglycaemia. Activation of hypoglycaemia-responsive glucose-sensing neurons in the 
Chapter 1 | General introduction and outline of the thesis
17
Ch
ap
te
r 1
ventromedial nucleus of the hypothalamus (VMH) is thought to initiate counterregulatory 
responses to hypoglycaemia (73). In animals, destruction of the VMH or local perfusion 
with glucose has been shown to markedly suppress counterregulatory hormone responses 
(74, 75), whereas local glucose deprivation stimulated these responses (76). Studies dating 
back to the 1990s suggested preservation of brain glucose transport during hypoglycaemia 
rather than a fall in healthy volunteers subjected to prior hypoglycaemia and in T1DM 
patients with near-normal glycaemic control and reduced hypoglycaemic awareness (77, 
78). Later studies using various neuroimaging techniques, however, found no evidence of 
altered glucose transport under these conditions (79-82). Recent observations that cerebral 
glucose metabolism is largely maintained during moderate hypoglycaemia in patients with 
longstanding type 1 diabetes (83-85) may suggest involvement of an alternative energy fuel, 
such as lactate, in the pathophysiology of IAH.  Lactate is used as fuel for the brain (86). There 
is evidence for increased brain lactate transport in patients with type 1 diabetes and IAH 
and in rats exposed to recurrent hypoglycaemia (85, 87). Furthermore, the use of lactate by 
glucose-sensing neurons of the VMH may interfere with glucose sensing (88, 89). The role of 
the brain in the development of IAH has been extensively reviewed elsewhere (90). 
As outlined above, IAH usually goes hand-in-hand with (severely) attenuated adrenaline 
responses to hypoglycaemia. Observations that prior hypoglycaemia suppresses adrenaline 
responses to subsequent hypoglycaemia and that avoidance of hypoglycaemia ameliorates 
these suppressed responses, is in line with similar mechanisms that underlie the impairment 
in symptomatic awareness. However, avoidance of hypoglycaemia may not fully restore 
defective adrenaline responses (56). Indeed, a study showing reduced plasma metanephrine 
levels in patients with type 1 diabetes and IAH suggests a reduced adrenomedullary capacity 
to secrete adrenaline (91). The observation that alpha- and beta-adrenergic blockade during 
antecedent hypoglycaemia does not blunt sympathoadrenal responses to subsequent 
hypoglycaemia (92) suggest a direct suppressive effect of antecedent adrenaline, but this 
suggestion could not be confirmed (93). 
Impaired awareness of hypoglycaemia is not only associated with reduced 
sympathoadrenergic responses to hypoglycaemia; there is also evidence for reduced 
sensitivity to adrenergic mediators. Several studies showed a reduced beta-adrenergic 
sensitivity following hypoglycaemia, both in patients with type 1 diabetes and in healthy 
subjects (47-51, 94-98). Reduced beta-adrenergic sensitivity was also observed in patients 
with IAH, restoration of which could be achieved after meticulous avoidance of hypoglycaemia 
(95). This reduced beta-adrenergic sensitivity is thought to be mediated through the beta2-
adrenergic receptor because of the role of the latter in hypoglycaemic symptom responses 
(47, 99-102). However, in a study by de Galan et al, vascular responses to local administration 
of a beta2-adrenergic agonist were not different between patients with type 1 diabetes with 
or without IAH or healthy volunteers (103).
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In this study (103), genetic differences in the beta2-adrenergic receptor were not taken 
into consideration and may have accounted for the negative results. The vulnerability for 
desensitization of the beta2-adrenerig receptor (ADRB2) is in part determined by genetic 
factors. Several single nucleotide polymorphisms have been described in the gene 
encoding the beta2-adrenergic receptor (104). Of these, especially the substitution of the 
amino acid arginine (Arg) for glycine (Gly) at codon 16 (known as Arg16Gly) is related to 
the desensitization of the receptor upon chronic stimulation (104, 105). There is conflicting 
literature on (chronic) desensitization of the beta2-adrenergic receptor in different diseases 
for example in hypertension, asthma and heart failure (106-109).
Whether genetic predisposition plays a role in the susceptibility to develop IAH remains to 
be elucidated. Danish investigators reported that patients with type 1 diabetes and a genetic 
variant of the ACE-genotype were at greater risk of severe hypoglycaemia, but found no 
associations with IAH (110-112). A Genome-Wide Association Study (GWAS) post-hoc analysis 
of the DCCT cohort revealed two other genotypes associated with increased risks of severe 
hypoglycaemia (113), but awareness of hypoglycaemia was not assessed in this study.
Morbidity and mortality of severe hypoglycaemia 
Glucose is the primary fuel for the brain. Any disruption of its supply to the brain puts the 
brain at immediate danger of dysfunction, although the glucose level below which this occurs 
is subject to considerable variation (114, 115). There are occasional case reports of serious 
brain damage induced by prolonged and profound hypoglycaemia and studies showing 
altered brain structure after severe hypoglycaemia (116-122), yet most patients with diabetes 
recover uneventfully from hypoglycaemia, even when complicated by coma or seizures. 
There are indications that severe hypoglycaemia constitutes a risk factor for persistent loss 
of cognitive function in the long term, in particular for the developing brain and the brain 
of the elderly (with type 2 diabetes) (123-126). A history of severe hypoglycaemia below 
the age of 5 is associated with poor performance on cognitive tests in children with type 1 
diabetes (127). Patients with type 2 diabetes are at increased risk of cognitive decline and 
dementia when they have a history of severe hypoglycaemia (125, 126, 128). In addition, 
insulin-treated adults with type 1 diabetes and a history of repeated severe hypoglycaemia 
have been found to perform slightly worse on an IQ test than patients without such a history 
(129). Prospective studies (4, 130, 131) and a cross-sectional study (132), however, have been 
unable to establish an association between severe hypoglycaemia and cognitive decline 
in adults or adolescents with type 1 diabetes. One factor explaining these mixed results is 
the concept of ‘hypoglycaemic preconditioning’, which posits that recurrent ‘mild’ episodes 
of hypoglycaemia cause changes in the brain that protects the brain against more severe 
insults (133).
Chapter 1 | General introduction and outline of the thesis
19
Ch
ap
te
r 1
It has been estimated that 4 to 10% of all deaths in type 1 diabetes occur under hypoglycaemic 
conditions (7-9). In most instances, death cannot be attributed directly to hypoglycaemia, 
but relates to the circumstances under which the hypoglycaemic event evolved, e.g. in traffic 
(134), during swimming or scuba diving, at heights, et cetera. A direct relation between 
hypoglycaemia and death has been proposed in the dead in bed syndrome, a rare disorder 
characterized by an unexpected death in a young, previously healthy, tightly controlled 
patient with type 1 diabetes, often with a history of recurrent (nocturnal) hypoglycaemia 
(135-137). Death in this syndrome is thought to be the result of a fatal ventricular arrhythmia 
caused by hypoglycaemia-induced lengthening of the QT interval (136, 138). The potential 
for hypoglycaemia to induce arrhythmia may also be clinically relevant for the type 2 diabetic 
population that is particularly prone to cardiovascular disease (139, 140). In patients with 
type 2 diabetes and coronary artery disease, hypoglycaemia has been found to cause 
myocardial ischaemia (141). In various large prospective studies (142) (143-145), as well 
as in a study conducted in the ICU (146, 147), that examined the effect of strict glycaemic 
control in type 2 diabetes, occurrence of severe hypoglycaemia was associated with excess 
mortality from both cardiovascular and non-cardiovascular causes (148, 149). It is presently 
discussed whether severe hypoglycaemia is a marker for an increased risk of adverse clinical 
outcomes associated with co-morbidities rather than a direct cause (150). The mechanisms 
by which hypoglycaemia may contribute to increased cardiovascular risk include enhanced 
thrombogenesis and pro-inflammatory processes, as reviewed elsewhere (151, 152). 
Diagnosis of impaired awareness of hypoglycaemia 
There are no easily applicable tests available to definitively establish the presence of impaired 
awareness of hypoglycaemia or defects in hormonal glucose counterregulation in daily 
clinical practice. Diagnosis of IAH is subject to clinical judgment, the assessment of which is 
clinically relevant because of its predictive value for future severe hypoglycaemic episodes 
(153-155). Self-reported failure to perceive hypoglycaemic symptoms has been associated 
with a higher incidence of severe hypoglycaemic events (156), underscoring patients’ 
capability for reliable self-diagnosis. Clinical signs suggestive of IAH include self-reporting of 
biochemical hypoglycaemia unaccompanied by symptoms, loss of autonomic symptoms as 
initial sign of hypoglycaemia, a (recent) history of severe hypoglycaemia, or the reporting that 
lower blood glucose levels are required to elicit symptoms. Nocturnal hypoglycaemias should 
be specifically addressed as they are more frequent than previously acknowledged and go 
typically unnoticed, because sleep suppresses symptomatic awareness (157). Continuous 
glucose monitoring (CGMS) may help to detect nocturnal or otherwise asymptomatic 
hypoglycaemia (158-160), although it should be acknowledged that the accuracy of such 
monitoring devices is relatively poor in the hypoglycaemic range (161, 162). It may prove 
valuable to ask spouses and family members whether they recognize hypoglycaemic events 
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earlier than the patient does, as this is suggestive for impaired awareness of hypoglycaemia. 
As irritability or even frank aggression may be a consequence of neuroglycopenia, such 
instances can be disturbing for both patients and their relatives, especially when the patient 
denies being hypoglycaemic and refuses to take appropriate action. A peculiar observation 
concerns the expression of odd behaviour by dogs whose owners are in a hypoglycaemic 
state, a phenomenon that might be exploited for hypoglycaemia alerting and is used to train 
dogs for the purpose of recognizing hypoglycaemia (163-165).
To identify patients at risk for IAH, health care providers should be aware of the risk factors. 
Consequent to the underlying pathophysiological mechanism, most clinical risk factors relate 
to the (antecedent) hypoglycaemia event rate, including a history of recurrent (nocturnal) 
hypoglycaemia, low HbA1c, absence of C-peptide and longer duration of diabetes. Advanced 
age is a risk factor, because the glucose threshold for autonomic symptoms shifts to lower 
glucose values and that for cognitive dysfunction to higher values in the elderly (28, 81, 166-
168). Men may be at greater risk for impaired awareness of hypoglycaemia than women, 
because they are more prone to develop counterregulatory defects (169). Given the relative 
stability of its prevalence over time (59-61), it is however questionable whether clinical risk 
factors alone explain the entire problem of impaired awareness of hypoglycaemia in people 
with type 1 diabetes. 
Treatment of impaired awareness of hypoglycaemia 
The best treatment to prevent impaired awareness of hypoglycaemia is by avoiding 
hypoglycaemic events. Both patients using insulin and their health care providers need to 
acknowledge the reality of hypoglycaemia, consider its risk factors and apply the principles 
of glycaemic control that are relevant to minimize the risk of hypoglycaemia. The latter 
means that patients are educated about hypoglycaemia, understand the dynamics of insulin 
and glucose, and perform self-monitoring of glucose (either by finger pricks or CGMS) and 
self-management (i.e., administer insulin in a dose adjusted to estimated need). Health-
care providers should ask patients about (severe) hypoglycaemic events and awareness 
of hypoglycaemia, offer the most appropriate insulin replacement therapy (e.g., insulin 
analogues, insulin pumps) and individualize glycaemic targets (170). Specific training 
programs that teach patients to integrate internal cues (i.e. symptoms) and external cues (e.g., 
insulin administration, food intake, physical exercise) may further help in reducing the risk of 
hypoglycaemia (171-173). Patients at high risk of hypoglycaemia, a history of problematic 
hypoglycaemia or with high-risk occupations may benefit from the use of technological 
innovations for glucose monitoring. Both CGMS and the flash glucose monitoring system 
have been shown to reduce the incidence of hypoglycaemia in patients with type 1 diabetes 
at high risk of hypoglycaemia (174-177).
Chapter 1 | General introduction and outline of the thesis
21
Ch
ap
te
r 1
For patients with IAH, particularly with a recent history of severe hypoglycaemia, short-
term scrupulous avoidance of hypoglycaemia has the potential to restore awareness of 
hypoglycaemia. Several studies have found that IAH is reversible, at least in part, when 
hypoglycaemic events are meticulously avoided for at least two to three weeks. Such a 
strategy has been shown to restore symptomatic awareness of hypoglycaemia, improve the 
adrenaline response to hypoglycaemia, shift the glycaemic thresholds for these responses to 
higher plasma glucose levels (56, 58, 178, 179) and normalize beta-adrenergic sensitivity (95, 
96). Not all counterregulatory defects respond to this strategy: glucagon responses typically 
remain unaffected, whereas adrenaline responses improve but usually do not normalize, 
possibly reflecting more or less permanent loss of adrenaline-releasing capacity (56). In 
daily practice, avoidance of hypoglycaemia often deteriorates glycaemic control, so that this 
strategy should be reserved for patients for whom the benefit of avoiding hypoglycaemia 
clearly outweighs the long-term harm of poorer metabolic control (6). Preferably, tightening 
of glycaemic control should be gradually re-introduced once awareness of hypoglycaemia 
has returned. 
Conclusion
In insulin-treated patients with diabetes, iatrogenic hypoglycaemia constitutes an important 
burden and remains the limiting factor in the glycaemic management of diabetes, despite 
the use of insulin analogues, insulin pumps and devices for glucose monitoring. Patients 
with recurrent hypoglycaemia are prone to develop impaired awareness of hypoglycaemia, 
a condition resulting from habituation to previous hypoglycaemia that affects 20-30% 
of patients with type 1 diabetes and creates a particularly high risk of severe, potentially 
hazardous, hypoglycaemia. However, classical risk factors that relate to the burden of 
antecedent hypoglycaemia and the integrity of counterregulatory function, cannot fully 
explain the occurrence of impaired awareness of hypoglycaemia, suggesting a role for a 
genetic predisposition. Further insight in this problem is needed to identify patients who are 
at the greatest risk and develop targeted strategies that support glucose counterregulation 
and – consequently – reduce the burden of hypoglycaemia.
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Outline of the thesis
As outlined above, classical risk factors insufficiently explain the whole burden of impaired 
awareness of hypoglycaemia among the population with type 1 diabetes. 
Cross-sectional studies from various regions and over a time span of more than 20 years 
reported fairly comparable prevalence figures for IAH among patients with type 1 diabetes 
(59-61). Even a more recent study in which patients used modern insulin analogues and 
insulin pumps that provide a more physiological way of insulin replacement therapy than 
injections with regular insulin, reported a prevalence that was within this range (62). It thus 
appears that affected patients retain (or revert back to) IAH over the longer term, which 
suggest an inherent, i.e. genetic, vulnerability towards its occurrence. Alternatively, it is also 
possible that IAH affects different populations over time. To investigate this in more detail, 
we used a validated questionnaire to estimate the prevalence of and risk factors for IAH in a 
contemporary cohort of patients with type 1 diabetes and then re-investigated these patients 
again 4 years later (chapter 2). 
We hypothesize that impaired hypoglycaemia awareness is partly determined by variation 
in genetic predisposition. Studies showing that the magnitude of beta2-adrenoceptor 
desensitization in response to repeated exposure to adrenergic stimulation is in part 
determined by genetic variation (180-184), provides important and particularly clinically 
relevant support for this concept. To address this issue, we performed various clinical studies. 
Adrenergic hypoglycaemic warning symptoms caused by (nor-) adrenaline are mediated 
through alpha- and beta-adrenergic receptors.  The previously studied reduced beta-
adrenergic signalling in type 1 diabetes (49-51, 98) and in patients with IAH (47, 48, 94-
96) may be mediated by downregulation of the beta2-adrenergic receptor (47, 99-101). 
Especially the beta2-receptor is particularly vulnerable to downregulation in response to 
repeated stimulation. Several single nucleotide polymorphism (SNP) in the gene encoding 
this receptor are associated with enhanced downregulation upon chronic stimulation, in 
particular on codon 16 (185, 186).  We therefore hypothesized that the prevalence of such a 
SNP would be higher in patients with IAH, which we tested in a small cohort of patients with 
type 1 diabetes who were genotyped (chapter 3). 
We then aimed to investigate whether people with this SNP would be more prone to 
receptor downregulation after exposure to recurrent antecedent hypoglycaemia, a stimulus 
known to suppress awareness of subsequent hypoglycaemia (25, 26). This hypothesis was 
tested in healthy volunteers who underwent two consecutive periods of clamped normo- 
or hypoglycaemia on day 1. The next day, we measured the local vasodilator response to 
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the selective beta2-adrenergic receptor agonist, salbutamol, to quantify beta2-adrenergic 
sensitivity. The results of these studies are described in chapter 4. 
Various studies have shown that men and women may differ with respect to the symptomatic 
response to hypoglycaemia and the vulnerability to the suppressive effect of antecedent 
hypoglycaemia on responses to subsequent hypoglycaemia (29, 187-189). We therefore 
investigated whether gender affected the haemodynamic responses to adrenaline, the most 
important hormone in the counterregulatory defence against hypoglycaemia in patients 
with type 1 diabetes. The results of these experiments are described in chapter 5. 
In chapter 6, we describe the results of a study that examined the impact of several potential 
genetic factors for impaired awareness of hypoglycaemia in people with type 1 diabetes. 
This study was conducted first to confirm previously obtained results described in chapter 
3 in a larger cohort of patients with type 1 diabetes. Furthermore, since there is linkage 
disequilibrium between various SNPs in the gene encoding the beta2-adrenergic receptor 
(185), a larger cohort would allow us to perform haplotype analysis. Finally, we investigated 
SNPs in the gene encoding the beta1-adrenergic receptor and various other genotypes that 
had been reported to be associated with the risk of severe hypoglycaemia (111, 113), the 
principal consequence of impaired awareness of hypoglycaemia. 
In 2008, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study reported 
excess mortality in patients with type 2 diabetes randomized to tight glucose control (142). 
It was suggested that the potential beneficial effects of optimal glucose control might – at 
least partly – have been offset by insulin-induced hypoglycaemia. Since then, various large 
prospective studies have shown robust associations between the occurrence of severe 
hypoglycaemia with increased all-cause and cardiovascular mortality as well as a range of 
other adverse outcomes in patients with type 2 diabetes (143-145). Because patients with 
type 1 diabetes and IAH are at the highest risk of severe hypoglycaemia, we were interested 
in the impact of this condition on mortality in patients with type 1 diabetes. We investigated 
this by combining follow-up data from two cohorts of patients with type 1 diabetes, for which 
we collaborated with a Danish study group (chapter 7).
Finally, Chapter 8 provides a summary of all results and puts these in perspective.
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Abstract
Introduction
The use of insulin analogues in basal bolus regimens and the increased use of subcutaneous 
insulin pumps have contributed to a reduced frequency of hypoglycaemia. It is less clear 
whether the prevalence of impaired awareness of hypoglycaemia (IAH) in type 1 diabetes 
(T1DM) has decreased. Here, we investigated awareness status prevalence and changes over 
time in a cohort of patients with T1DM.  
Methods 
IAH status was assessed in patients with T1DM, recruited from the outpatient department, at 
baseline and after 4 years of follow up, using a validated questionnaire. A medical file review 
was performed to obtain information on clinical characteristics.
Results
A total of 485 patients completed the first questionnaire, of which 158 (32.5%) were classified 
as having IAH.  Patients with IAH were more frequently male, older, had lower HbA1c values, 
a longer duration of diabetes, chronic renal failure and neuropathy. IAH was still common in 
patients with HbA1c levels ≥8,5% (69mmol/mol), 23,6% of whom had IAH, and more than half 
of the 158 patients with IAH had an HbA1c above 7.5% (58 mmol/mol). 342 patients completed 
the second questionnaire (71%). The number of patients with IAH remained stable over time 
(33.0%). Of the 103 patients with IAH at baseline, only 26 (25.0%) had regained awareness. 
Of the patients with normal awareness at baseline, awareness status remained unchanged 
in 203 (84.9%) patients, whereas 36 (15.1%) had developed IAH. Patients with persistent IAH 
were more often male, leaner, older, and had longer duration of diabetes, lower HbA1c and 
decreased renal function compared to patients without IAH at both time-points. 
Conclusion
IAH remains highly prevalent in people with type 1 diabetes and is persistent over time in three 
out of four patients. The fact that the prevalence is stable despite improvements in insulin 
therapy and decreased risks for hypoglycaemia may indicate that genetic predisposition is a 
determinant of IAH. 
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Introduction
Hypoglycaemia remains an important limitation of insulin treatment in patients with type 1 
diabetes (T1DM), but is virtually unavoidable in the pursuit of optimal glycaemic control (1). 
Timely recognition of hypoglycaemia is critical to allow early counter regulatory measures 
(i.e. ingestion of carbohydrates) and to prevent progression to severe hypoglycaemia. 
Studies dating back to the 1980s have indicated that 20-30% of patients with longstanding 
type 1 diabetes have diminished ability to detect hypoglycaemia, a syndrome known as 
impaired awareness of hypoglycaemia (IAH) (2, 3). IAH is thought to result from habituation 
to recurrent antecedent exposure to hypoglycaemia and increases the risk for (particularly 
severe) hypoglycaemia (4), initiating a vicious cycle.  
A brief period of scrupulous avoidance of hypoglycaemia has been shown to effectively 
restore symptomatic awareness of hypoglycaemia and ameliorate associated defects in 
hormonal counter regulation (5-8). In the past decade, the use of insulin analogues in basal 
bolus regimens and the increased use of subcutaneous insulin pumps have contributed to a 
reduced frequency of hypoglycaemia (9-12). Nevertheless, recent studies reporting IAH among 
20-28% of patients with T1DM suggest limited impact of innovations in therapy for T1DM 
on the prevalence of IAH (13-16). It is currently unknown whether awareness status changes 
over time in individual patients or in which proportion of patients with IAH the unawareness 
persists.  To address this study question, we assessed the self-reported frequency of IAH at 
two different time points in a follow-up study of a cohort of patients with type I diabetes, and 
determined associated risk factors. 
Materials and Methods
Participants
Patients with T1DM were recruited from the outpatient diabetes clinic of the Radboud 
University Medical Center from 2006 through 2008. Patients who consented to participate 
were asked to complete the clamp-validated Dutch version of the Clarke questionnaire; a 
questionnaire that consists of five questions with a score of 0-1 indicating normal awareness 
and a score ≥3 indicating IAH (17, 18). All patients who completed the questionnaire 
were asked to fill out the questionnaire again, approximately four years later. The second 
questionnaire also assessed smoking behaviour and alcohol and coffee consumption. A 
medical file review was performed to obtain information on clinical characteristics such as 
medication use, laboratory results, complications due to diabetes, and comorbidities. All 
participants signed informed consent for participation and the Institutional Review Board of 
the Radboud University Medical Center approved the study. 
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Statistical analyses
Data are presented as means ± standard deviation or frequencies (%). Demographic and clinical 
characteristics were compared between patients with IAH to those without IAH, with chi-square 
tests and Student t-tests where appropriate. The Mann-Whitney test was used for variables that were 
not normally distributed. Logistic regression was performed to calculate odds ratios (ORs) and 95% 
confidence intervals (CI). All analyses were performed using SPSS v. 22.0.0.1 (Chicago, IL USA).
Results
Characteristics of the patients and prevalence of IAH
A total of 485 patients completed the first questionnaire, of which 158 (32.5%) were classified 
as having IAH.  Table 1 shows the characteristics of patients with or without IAH for the first 
questionnaire. Patients with IAH were more frequently male, older, had lower HbA1c values 
and a longer duration of diabetes. The proportion of patients with microvascular diabetic 
complications was also higher in the IAH group, but this was only statistically significant 
for neuropathy and renal failure. At the time of the first questionnaire, the large majority of 
patients used short- and long-acting insulin analogues (93% and 90%, respectively), whereas 
30% of patients were on insulin pump therapy. Treatment with insulin analogues or insulin 
pumps was not associated with the presence or absence of IAH.
Figure 1. shows the prevalence of IAH according to HbA1c. Patients with lower HbA1c levels 
were more likely to have IAH than those with higher HbA1c. However, IAH was still common 
(23,6%) in patients with HbA1c levels ≥8,5% (69mmol/mol), and more than half of the 158 
patients with IAH had an HbA1c above 7.5% (58 mmol/mol) (figure 2).  
Figure 1: Prevalence of IAH according to HbA1c categories in 2006 (IAH baseline) and in 2010 (IAH follow-up) 
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Table 1. Demographic and clinical characteristics of 485 type 1 diabetes patients according to hypoglycaemia 
awareness status 
Aware
(n=327)
IAH
(n=158)
P-value OR (95% CI)
Male gender 142 (43.4) 84 (53.2) 0.04 1.48 (1.01-2.17)
Age, yrs 44.1 ± 14.1 47.9 ± 12.6 0.004 1.02 (1.00-1.04)
Duration diabetes, yrs 23.9 ± 12.7 28.8 ± 11.9 <0.0001 1.03 (1.02-1.05)
BMI, kg/m2 26.0 (23.2-28.6) 24.9 (23.1-28.0) 0.27 0.99 (0.94-1.04)
HbA1c, mmol/l 64 (56-72) 61 (53-67) 0.0003 0.71 (0.59-0.86)
Neuropathy 109 (34.5) 68 (44.2) 0.04 1.50 (1.01-2.23)
Macrovascular disease 41 (12.7) 27 (17.1) 0.20 1.41 (0.83-2.40)
Renal Failure * 7 (2.2) 12 (7.6) 0.004 3.69 (1.42-9.56)
Retinopathy 141 (44.6) 68 (43.6) 0.83 0.96 (0.65-1.41)
Benzodiazepine use 9 (2.8) 10 (6.3) 0.06 2.34 (0.93-5.89)
Beta-blocker use 51 (15.9) 21 (13.4) 0.47 0.82 (0.47-1.42)
RAS inhibition 81 (25.2) 33 (20.9) 0.29 0.78 (0.49-1.24)
Short-acting analog 287 (92.9) 138 (93.9) 0.69 1.18 (0.53-2.62)
Long-acting analog 197 (90.8) 92 (87.6) 0.38 0.72 (0.34-1.51)
CSII 96 (29.8) 48 (30.6) 0.86 1.04 (0.69-1.57)
Values are mean ± standard deviation, median (interquartile range) or n (%)
Note: Numbers may not add up to the total due to missing values
*eGFR(MDRD)<60ml/min
HbA1c category 
Figure 2: Proportion of patients with IAH (n=158) according to HbA1c category
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IAH and risk factors over time
342 Patients (71%) completed the second questionnaire, approximately 4 years later. Non-
responders differed from responders with respect to prevalence of IAH (38.5 vs. 30.0%, 
p=0.071), glycaemic control (HbA1c, 8.3 (76mmol/mol) vs. 7.8%, (62 mmol/l), p=0.007) and age 
(45.9 vs. 50.5 years, p=0.0009). Among responders, the second questionnaire disclosed IAH 
among 113 patients (33.0%) indicating that the proportion of patients with IAH was about 
stable over time. The use of pump therapy increased between the time of the first and second 
questionnaire (30% vs. 36%), but its use remained not associated with IAH. Apart from lower 
BMI and alcohol use being associated with IAH, associations with IAH obtained from the 
second questionnaire were consistent with the first (data not shown).
Of the initial 158 patients with IAH, 103 patients completed the second questionnaire (65%). 
Of these, 77 (75.0 %) remained unaware, whereas 26 (25.0%) regained awareness. Of the 
initial 327 patients without IAH, 239 completed the second questionnaire (73%). Of these 
patients, awareness status remained unchanged in 203 (84.9%) patients, whereas 36 (15.1%) 
had developed IAH. Two out of 9 (22.2%) patients with IAH who switched from multiple daily 
injections to pump therapy regained awareness, which was quite similar - 25.8% - for the 62 
patients with IAH who remained on multiple daily injection therapy. We did not identify any 
demographic or clinical factors significantly associated with changes in awareness status.
Characteristics of patients with persistent IAH
We then evaluated specific risk factors that were associated with stable awareness, either 
impaired or normal, over time. Patients with persistent IAH were more often male, non-obese 
and older, and had longer duration of diabetes, lower HbA1c and decreased renal function 
compared to patients without IAH at both time-points (table 2). There were no other risk 
factors that were specifically associated with either persistent IAH or normal awareness. 
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Table 2: Demographic and clinical characteristics of patients with unchanged awareness status.
Persistent
Aware
(n=203)
Persistent 
IAH
(n=77)
Chanced 
awareness
Status
(n=62)
P-value OR (95% CI)
Male gender 78 (38.0) 43 (56.6) 29 (46.8) 0.005 0.47 (0.28-0.80)
Age, yrs 49.0 ± 13.6 53.7 ± 12.4 50.8 ± 12.5 0.005 1.03 (1.01-1.05)
Duration diabetes, yrs 27.6 ± 12.3 33.5 ± 11.8 29.5 ± 12.9 0.000 1.04 (1.02-1.06)
BMI, kg/m2 26.3 (21.3-31.3) 25.0 (20.0-30.0) 26.3 (21.3-31.3) 0.002 0.88 (0.81-0.95)
HbA1c, mmol/mol 64 (56-73) 61 (54-65) 62 (46-78) 0.024 0.74 (0.56-0.96)
Neuropathy 90 (51.4) 46 (64.8) 30 (54.5) 0.056 1.74 (0.98-3.07)
Macrovascular disease 36 (18.1) 17 (22.7) 8 (13.3) 0.39 1.33 (0.69-2.54)
Renal failure* 10 (5.6) 15 (21.7) 8 (13.3) 0.000 4.67 (1.98-11.0)
Benzodiazepine use 7 (3.5) 1 (1.3) 1 (1.7) 0.34 0.37 (0.05-3.07)
Retinopathy 108 (56.8) 35 (50.7) 29 (46.8) 0.38 0.78 (0.45-1.36)
Beta-blocker use 44 (22.2) 13(17.3) 12 (19.4) 0.38 0.73 (0.37-1.46)
RAS inhibition 53 (26.6) 24 (32.0) 15 (25,0) 0.38 1.30 (0.73-2.31)
Short-acting analog 176 (92.6) 69 (98.6) 55 (96.5) 0.068 5.49 (0.71-42.54)
Long-acting analog 120 (95.2) 42 (91.3) 54 (94.4) 0.33 0.52 (0.14-1.95)
CSII 69 (34.8) 29 (38.7) 23 (38.3) 0.56 1.18 (0.68-2.04)
≥3 glasses of alcohol per day 9 (4.4) 6 (8.0) 2 (3.3) 0.24 1.88 (0.65-5.14)
Current smoking 32 (15.8) 21 (28.8) 9 (15.3) 0.16 2.16 (1.15-4.06)
Values are mean ± standard deviation, median (interquartile range) or n (%)
OR calculated between persistent IAH and persistent normal awareness.  
Note: Numbers may not add up to the total due to missing values
*eGFR(MDRD)<60ml/min
Discussion
This study shows that despite better treatments, the prevalence of impaired awareness 
of hypoglycaemia remains stable, affecting one in three patients. In most patients IAH is 
persistent over time. These findings emphasize that IAH remains a major problem for patients 
with type 1 diabetes. 
 We found that the vast majority of patients did not change with respect to the presence or 
absence of IAH. Only a quarter of patients with IAH had regained awareness of hypoglycaemia. 
Conversely, the chance of developing IAH among patients with longstanding diabetes but 
without IAH was relatively low at ~15%. 
The prevalence of IAH in our cohort was somewhat higher than reported previously. Older 
age, lower HbA1c values and longer duration of diabetes are well-known risk factors for the 
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development of IAH (14, 15, 19). Patients included for the present analysis were somewhat 
older, had longer duration of diabetes and lower HbA1c values compared to most other 
cohorts (4, 14, 15), which may explain the difference in prevalence. Furthermore, these are 
patients from a tertiary referral clinic and IAH may be one of the referral reasons. As reported 
earlier, low HbA1c was a risk factor for IAH. However, high HbA1c values were by no means 
protective against IAH development. Indeed, our analysis showed that IAH affects about a 
quarter of patients with an HbA1c>64 mmol/mol (8%). In fact, we found that more than half 
of all patients with IAH included in this analysis had suboptimal or poor glycaemic control. 
Relatively few patients changed from one ‘awareness category’ to the other. The majority of 
patients (75%) who were classified as having IAH by the first questionnaire retained IAH when 
questioned several years later. This is roughly in parallel with data from two smaller Danish 
studies, in which awareness status remained unchanged after one year in ~74% of patients 
with type 1 diabetes and in 77% of patients with insulin-treated type 2 diabetes (20, 21). 
Importantly, the proportion of patients who ‘developed’ IAH when this was initially absent 
was 15%. This may be low, but should not be neglected. There were, however, no specific 
baseline risk factors other than classical risk factors that discriminated these patients from 
those not developing IAH.
A limitation of our study is that information on IAH was self-reported. However, the 
questionnaire that we used has an 85% sensitivity for the detection of IAH and has been 
validated by hypoglycaemic clamps (18). Another limitation is that follow-up after four years 
was incomplete. Patients who only completed the first questionnaire were more likely to 
have IAH, had higher HbA1c values and were younger than patients who completed both 
questionnaires. To what extent these differences would have affected the change in awareness 
state and ultimate prevalence of IAH cannot be determined. Finally, our assessments 
were performed largely before the clinical introduction of continuous glucose monitoring 
devices. While the use of continuous glucose monitoring may ameliorate IAH by reducing the 
hypoglycaemic burden (22, 23), a recent study found no effect of the use of glucose sensors 
in patients with IAH, despite a twofold reduction in the rate of severe hypoglycaemia (24). 
In conclusion, impaired awareness of hypoglycaemia remains highly prevalent in people with 
type 1 diabetes and is persistent over time in three out of four patients. The stable prevalence 
suggests that genetic predisposition is a determinant of IAH, although its precise components 
still have to be elucidated. Clinicians should be aware that IAH is highly prevalent, both in 
those with tight as in those with ‘suboptimal’ glucose control.  
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The Arg16Gly variant of the beta2-adrenergic 
receptor predisposes to hypoglycaemia 
unawareness in type 1 diabetes mellitus
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Abstract
Hypoglycaemia unawareness has been linked to desensitization of the beta2-adrenergic 
receptor. Desensitization of the beta2-adrenergic receptor (ADRB2) is genetically determined 
by the Arg16Gly variant of this receptor. We tested the hypothesis that hypoglycaemia 
unawareness is more common among patients homozygous for the Gly16 variant. 
We performed genotyping of the A265G (Arg16Gly) polymorphism in the ADRB2 gene in 85 
patients with type 1 diabetes and classified them according to hypoglycaemia awareness 
status.
A total of 45 Patients (53%) were homozygous for Gly16, 32 patients (38%) were heterozygotes 
and eight patients (9%) were homozygous for Arg16. Hypoglycaemia unawareness was 3.4-
fold more common among patients homozygous for Gly16 than among patients with other 
variants of the Arg16Gly polymorphism (p=0.014).
We conclude that patients with type 1 diabetes who carry two alleles of the Gly16 variant of 
ADRB2 are at increased risk of developing hypoglycaemia unawareness. Future studies are 
required to confirm these results in larger, independent populations.  
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Introduction
Hypoglycaemia unawareness, defined as the absence of appropriate autonomic warning 
symptoms before the onset of neuroglycopenia, is a common complication of insulin therapy 
in type 1 diabetes mellitus and occurs in approximately 25% of patients. Hypoglycaemia 
unawareness considerably increases the risk of severe complicated hypoglycaemia and is 
often viewed as a limiting factor for intensive insulin treatment in patients with diabetes 
(1). This increased hypoglycaemic risk is in part the result of typical defects in hormonal 
counterregulation. In patients with hypoglycaemia unawareness, hypoglycaemia fails to elicit 
a glucagon response whereas the epinephrine response is attenuated and shifted towards 
lower plasma glucose concentrations. In addition to an attenuated epinephrine response, 
several studies have reported reduced beta-adrenergic sensitivity in the pathogenesis of 
hypoglycaemia unawareness (2, 3).
Reduced beta-adrenergic sensitivity may be the result of beta-adrenergic receptor 
desensitization upon chronic stimulation caused by repeated hypoglycaemia-induced 
release of catecholamines (4). In vitro studies have indicated that reduced beta-adrenergic 
sensitivity is mediated through the beta2-adrenergic receptor (5). The vulnerability for 
desensitization of the beta2-adrenerig receptor (ADRB2) is in part determined by genetic 
factors. Several single nucleotide polymorphisms have been described in the gene encoding 
the beta2-adrenergic receptor (6). Of these, the substitution of the amino acid arginine 
(Arg) for glycine (Gly) at codon 16 (known as Arg16Gly) is related to the desensitization of 
the receptor upon chronic stimulation (6, 7). In the present study, we tested the hypothesis 
that hypoglycaemia unawareness is more common among type 1 diabetic patients who are 
homozygous for Gly16 compared to patients who are heterozygous Arg16Gly or homozygous 
Arg16.
Materials and methods
Participants
This study was performed in a prospective cohort of patients with type 1 diabetes (8). 
Participants were included in this cohort from 1994 to 1998 and were recruited from the 
outpatient diabetes clinics of the Radboud University Nijmegen Medical Center and affiliated 
hospitals. The study was approved by the local ethics committee and all patients gave 
informed consent prior to participation. Inclusion criteria were onset of diabetes before 
the age of 40 years, insulin treatment within 1 year of diagnosis, duration of diabetes 5-12 
years, age 18-40 years, blood pressure <140/90 mmHg, no antihypertensive medication, and 
absence of macrovascular or microvascular diseases. In a large subgroup of these patients, 
ADRB2 genotyping was performed. All genotyped patients were asked to participate in 
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this study by completing a questionnaire to identify hypoglycaemia awareness status (see 
below). The questionnaires were collected in 2006. 
ADRB2 genotyping  
DNA was extracted from whole blood using the QIAamp® Blood Kit (Qiagen Inc., Fremont, 
California, USA). Genotyping of the A265G (rs1042713, Arg16Gly) polymorphism was 
performed using a multilocus genotyping assay for candidate markers of cardiovascular 
disease risk (9) (Roche Molecular Systems Inc., Pleasanton, California, USA). 
Assessment of hypoglycaemia awareness status
All patients completed a Dutch translation (10) of the questionnaire developed by Clarke et 
al. (11). This questionnaire has been validated for detecting hypoglycaemia unawareness 
(10). The questionnaire consisted of five multiple-choice questions, the answer to which 
could be awarded 0 points or 1 point, indicating awareness or unawareness, respectively. 
The first item was based on the experience of a loss of symptoms. The second item was 
based on the patient’s ability to recognize hypoglycaemia on the basis of symptoms, 
defining the answer “always” as normal awareness and the answers “never” or “sometimes” 
as unawareness.  The third item was based on how low blood glucose needed to be for the 
patient to experience symptoms, defining a level <3 mmol/l as unawareness. The fourth item 
was based on the history of hypoglycaemia in the past months in which the patient was too 
confused, disoriented or lethargic to perform self-treatment. The fifth item was based on the 
history of severe hypoglycaemia in the past year that was complicated by unconsciousness 
or seizures and/or required glucagon or intravenous glucose treatment.  For calculation 
purposes only, the total scores were dichotomized, so that patients with a score <3 were 
considered to have normal awareness and those with a score of 3 or above were considered 
to be hypoglycaemia unaware. 
Statistics
Statistical analysis was performed using SPSS software package for windows, version 15.0 
(SPSS, Chicago, Illinois USA). Genotype frequencies were tested for the Hardy-Weinberg 
equilibrium. We used chi2 test for the categorical comparisons of the data. Differences in 
the means of continuous measurements were tested by two-tailed Student’s t-test. Relative 
risk was estimated by the odds ratios (ORs) and their 95% confidence intervals (95% 
CIs). A multiple logistic regression analysis was performed using the following variables 
as explanatory variables: Arg1Gly  polymorphism, duration of diabetes, age and HbA1c. 
Differences were considered statistically significant at P<0.05. 
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Results
A total of 92 patients gave informed consent for DNA analysis. The Arg16Gly polymorphism 
of the ADRB2 was successfully genotyped in 85 patients (92%). Genotype frequencies did not 
deviate from the Hardy-Weinberg equilibirum. All the 85 patients returned the questionnaire 
assessing awareness status. Table 1 shows the clinical characteristics according to awareness 
status. Participants classified as hypoglycaemia unaware were slightly older, had longer 
disease duration, and tended to be in better glycaemic control than those classified as 
hypoglycaemia aware, but none of these differences reached statistical significance.  
Table 1: Clinical characteristics of participating patients according to hypoglycaemia awareness status. 
Unaware Aware p-value
N (male/female) 26 (15/11) 59 (29/30) NS
Age (years) 40.2 (6.1) 38.3 (6.9) NS
Duration of diabetes (years) 17.6 (3.4) 16.4 (3.1) NS
BMI (kg·m-2) 24.5 (2.4) 23.5 (3.0) NS
HbA1c (%) (n=70, 82%) 7.69 (1.1) 8.15 (1.2) NS
Unawareness score 3.5 (0.7) 0.69 (0.8) P<0.001
Data are presented as mean (± SD)
Of the 85 patients, 45 were homozygous for Gly16 (53%), 32 were heterozygous for Arg16Gly 
(38%) and eight were homozygous for Arg16 (9%).  Nineteen of the Gly16 homozygous patients 
(42%) were classified as being hypoglycaemia unaware compared with five (16%) and two 
(25%) of the Arg16Gly heterozygous and Arg16 homozygous patients, respectively Patients 
who were homozygous for Gly16 were 3.4-fold more likely to be hypoglycaemia unaware 
than patients without this variant (OR: 3.45, 95% CI: 1.26-9.44; P=0.014). (Figure 1). The 
nominal regression analysis showed a chi2 for covariates of 13.345 on 5 degrees of freedom 
(P=0.02). Gly16 homozygosity is solely and independently associated with hypoglycaemia 
unawareness (OR 5.21, 95% CI: 1.45-18.64; P=0.011). 
Figure 1: Allelic frequency of the ADRB2 polymorphism according to awareness status. P=0.014; OR: 3.45, 95% CI: 
1.26–9.44.
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Discussion
The results of this study show that hypoglycaemia unawareness assessed on the basis of a 
validated questionnaire was more than three times more common among type 1 diabetic 
patients who are homozygous for the Gly16 variant of the ADRB2 gene than patients with 
other genotypes at this position. This is the first study to report a relationship between the 
ADRB2 Arg16Gly polymorphism and hypoglycaemia unawareness.
Our data are in accordance with in vitro data showing enhanced receptor downregulation 
on chronic stimulation of the homozygous Gly16 variant of the receptor compared with the 
Arg16 homozygous genotype [6]. In vivo studies using different agonists in various disease 
states have, however, shown conflicting results, with some reporting that the desensitization 
process is stronger in homozygous Arg16 carriers (7, 12). The discrepancy between these 
studies may be explained by a contribution of highly sensitive polymorphic receptors 
(i.e. Gly16) that are ‘predesensitized’ by endogenous catecholamines, making further 
desensitization by exogenous agonists impossible. Furthermore, there is strong linkage 
disequilibrium between the single nucleotide polymorphisms at codons 16 and 27 of ADRB2, 
although in vivo data suggest predominance of the effects of the polymorphism at codon 16 
over that at codon 27(6). Nevertheless, investigating naturally occurring haplotypes instead 
of isolated genotypes might provide a better insight in the functionality of the ADRB2 in vivo 
(12). 
Our data seem at odds with a recent study (13), in which we failed to find evidence for 
reduced beta2-adrenergic receptor sensitivity in a group of 22 type 1 diabetic patients, 10 
of whom were classified as hypoglycaemia unaware. Better monitoring of glucose values 
with consequent hypoglycaemia avoidance in the week before beta2-adrenergic sensitivity 
testing might have been relevant, but as genotyping was not performed, the play of chance 
seems to be the most likely explanation for the negative results.
Although it should be acknowledged that the ‘cause’ of unawareness is probably multifactorial, 
our regression analysis identified Gly16 homozygosity as the only independent factor. 
Limitations of our study include the small sample size (n=85), which obviates confirmation in a 
larger study, the exploratory nature of association studies, and the lack of an easily accessible 
‘gold standard’ for assessing hypoglycaemia awareness status. The time-consuming nature 
of the hypoglycaemic clamp, which is accepted as the most reliable method to assess 
hypoglycaemia awareness, however, makes it impractical to use it in larger cohort studies. 
We used a standardized questionnaire that has been reported to correlate reasonably well 
with the hypoglycaemic clamp (10, 11). 
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In summary, this study shows an association between ADRB2 genotype and hypoglycaemia 
unawareness. Gly16 homozygous patients seem particularly susceptible for developing 
hypoglycaemia unawareness. If confirmed in larger studies, these findings may have practical 
implications, in that additional caution may be warranted to avoid hypoglycaemia in Gly16 
homozygous patients, whereas further optimization of glycaemic control may be achievable 
in patients without the variant. A study with larger numbers of patients, investigating naturally 
occurring haplotypes of the ADRB2 is therefore needed to confirm these data. 
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The eﬀ ect of antecedent hypoglycaemia 
on beta2-adrenergic sensitivity in healthy 
participants with the Arg16Gly polymorphism 
of the beta2 adrenergic receptor
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Abstract
Introduction
Homozygosity for glycine at codon 16 (GlyGly) of the beta2-adrenergic receptor may alter 
receptor sensitivity upon chronic stimulation and has been implicated in the pathogenesis 
of hypoglycaemia unawareness. We compared the effect of antecedent hypoglycaemia on 
beta2-adrenergic receptor sensitivity between GlyGly participants and those with arginine 16 
homozygosity (ArgArg) for the beta2-adrenergic receptor. 
Methods
We enrolled 16 healthy participants, who were either GlyGly (n=8) or ArgArg (n=8) or ArgArg 
(n=8). They participated randomly in two 2 day experiments. Day 1 consisted of two 2 -h 
hyperinsulinaemic hypoglycaemic (2.8 mmol/l) or euglycaemic (4.8 mmol/l) glucose clamps. 
On day 2, we measured the forearm vasodilator response to the beta2-adrenergic receptor 
agonist salbutamol and the dose of isoprenaline required to increase the heart rate by 25 
bpm (IC25).
Results
The vasodilator response to salbutamol tended to be greater after antecedent hypoglycaemia 
than after euglycaemia (p=0.078), consistent with increased beta2-adrenergic receptor 
sensitivity. This effect was driven by a significant increase in beta2-adrenergic receptor 
sensitivity following hypoglycaemia compared with euglycaemia in ArgArg participants 
(p=0.019), whereas no such effect was observed in the GlyGly participants. Antecedent 
hypoglycaemia tended to decrease the IC25 in ArgArg participants, whereas the reverse 
occurred in the GlyGly participants (GlyGly vs ArgArg group p =0.047). 
Conclusion
Antecedent hypoglycaemia did not affect beta2-adrenergic receptor sensitivity in healthy 
GlyGly participants, but increased it in ArgArg participants. If these results also hold for 
participants with type 1 diabetes, such an increase in beta2-adrenergic receptor sensitivity 
may potentially reduce the risk of repeated hypoglycaemia and the subsequent development 
of hypoglycaemia unawareness in ArgArg diabetic participants.  
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Introduction
Despite important advances in insulin treatment and glucose control, hypoglycaemia remains 
a fact of life for many patients with type 1 diabetes. Repeated hypoglycaemic episodes 
are known to impair glucose counter-regulatory defences and to reduce hypoglycaemic 
awareness (1-3). Indeed, impairments in counterregulatory hormone responses to, and 
symptomatic perception of, insulin-induced hypoglycaemia can be induced by as few as 
two hypoglycaemic episodes, even in healthy participants (4-6). However, although most 
patients with type 1 diabetes experience hypoglycaemia on a fairly regular basis, clinically 
relevant hypoglycaemia unawareness affects ‘only’ about 25% of patients (7). This suggests 
involvement of other factors that determine the susceptibility to developing hypoglycaemia 
unawareness. 
Genetic factors have been implicated in the risk for hypoglycaemia and hypoglycaemia 
unawareness in patients with type 1 diabetes (8, 9). We recently found that the prevalence 
of hypoglycaemia unawareness was in part determined by a SNP in the gene encoding the 
beta2-adrenergic receptor (ADRB2) (10). Thus, patients who were GlyGly at codon 16 of the 
beta2-adrenergic receptor were more likely to report hypoglycaemia unawareness than 
those who were ArgGly or ArgArg. 
The SNP occurring at position 46 of ADRB2, encoding for arginine or glycine at the N-terminus 
(codon 16) of the beta2-adrenergic receptor, may determine the degree to which beta2-
adrenergic receptors lose sensitivity when chronically stimulated. Although in vitro studies 
have displayed discrepant results (11), most in vivo data indicate that substitution of 
glycine for arginine at codon 16 reduces sensitivity of the beta2-adrenergic receptor upon 
chronic stimulation (12, 13). This might be a potential mechanism in the development of 
hypoglycaemia unawareness since recurrent hypoglycaemic episodes and the consequent 
release of catecholamine’s may alter beta2-adrenergic receptor sensitivity. Reduced beta-
adrenergic sensitivity has been reported in relation to hypoglycaemia unawareness, based 
on reduced heart rate responses to isoprenaline, a non-selective beta-adrenergic agonist (14-
18). In addition, there is some suggestion that this reduced sensitivity was mediated through 
the beta2-adrenergic receptor (19, 20). Mixed effects were seen in healthy participants, with 
one study showing reduced (21), and another showing increased, beta-adrenergic sensitivity 
(15) after a period of hypoglycaemia. The effect of antecedent hypoglycaemia on beta2-
adrenergic sensitivity alone has not been determined. Further, it could be argued that genetic 
variation of the beta2-adrenergic receptor explains the abovementioned disparate effects of 
hypoglycaemia on beta-adrenergic sensitivity in patients and healthy participants.
The aims of this study were first to investigate whether two episodes of antecedent 
hypoglycaemia, a stimulus known to induce hypoglycaemia unawareness (4, 5), would 
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decrease next day beta2-adrenergic sensitivity in healthy participants, and second, to 
investigate this more particularly in participants who were GlyGly compared with ArgArg. 
Methods
Participants
Healthy participants (n=96) were selected by advertisement and genotyped for the Arg/Gly 
polymorphism in ADRB2. Of these, 16 participants were enrolled in the present study: eight 
GlyGly (one male, mean age 22 ± 1 years, mean BMI 21.2 ± 1.3 kg/m2) and eight ArgArg (four 
males, mean age 22 ± 1 years, mean BMI 21.2 ± 0.4 kg/m2). None of the participants were 
allowed to use any medication except oral contraceptives. They were asked to abstain from 
alcohol and caffeine containing products for 24 h and from food intake at least 10 h before 
experiments took place. All participants gave their written informed consent. The study was 
approved by the Radboud University Nijmegen Medical Centre Medical Ethics Committee 
and carried out in accordance with the principles of the Declaration of Helsinki as revised in 
2000.
Experimental design 
We performed a randomised controlled crossover study, comparing the effects of antecedent 
hypoglycaemia with those of antecedent euglycaemia. Participants participated in two 
experiments, each consisting of two consecutive days and scheduled at least 3 weeks 
apart. Female participants were studied during the same period of the menstrual cycle. The 
aim of day 1 was to induce hypoglycaemia unawareness by two consecutive episodes of 
hypoglycaemia, whereas the control experiment consisted of two comparable episodes of 
euglycaemia. The aim of day 2 was to quantify beta2-adrenergic and overall beta-adrenergic 
sensitivity by measuring the vasodilator response to salbutamol and the heart rate response 
to isoprenaline, respectively. All experiments took place at the Clinical Research Centre 
Nijmegen (CRCN) in a temperature controlled room (temperature 23-24 °C).
First experiment day 1:
All participants were admitted to the CRCN at 08:00 hours after an overnight fast. Two 
indwelling catheters were inserted intravenously. One catheter was placed in retrograde 
fashion into a dorsal hand vein for blood sampling. This hand was placed in a heated box 
(55-60°C) to obtain arterialised venous blood (22). The second catheter was inserted in the 
antecubital vein of the contralateral arm for infusion of insulin (Actrapid, Novo Nordisk, 
Bagsvaerd, Denmark) and glucose. At t=0 min, infusion of insulin was initiated at a rate of 
60 mU m-2 min-1 after a bolus of 1 U. Plasma glucose was maintained at predetermined 
levels using a variable infusion of glucose 20%, based on plasma glucose levels measured 
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in duplicate at 5 min intervals by the glucose oxidase method using a Beckman Glucose 
Analyzer II (Beckman Instruments, Fullerton, CA). The plasma glucose target was ~4.8 mmol/l 
during the euglycaemic clamps and ~2.8 mmol/l during the hypoglycaemic clamps. These 
levels were reached within 45 min and then maintained for 120 min. Subsequently, the 
insulin infusion was discontinued, euglycaemia was maintained (euglycaemia) or restored 
(hypoglycaemia), and the participants received a small snack. After 120 min, the clamp 
procedure was repeated in the afternoon. At t=450 min, the insulin infusion was terminated, 
glucose was continued as required to restore and maintain euglycaemia and participants 
received a carbohydrate-rich meal before they left the research unit at approximately 18:00 
hours. Arterialised blood was sampled for measurement of catecholamines, insulin, glucagon 
and cortisol at baseline, and at t=45, 105, 165, 330, 390 and 450 min. Before initiation of, and at 
20-min intervals during, the clamp procedures, the appearance of hypoglycaemic symptoms 
was checked using a semi-quantitative symptom questionnaire (23) consisting of non-
specific (not feeling well, nausea, headache), adrenergic (tremor, palpitations), cholinergic 
(hunger, sweating, dry mouth, tingling), neuroglycopaenic (difficulty speaking, blurred vision, 
difficulty to concentrate, confusion, tiredness, weakness) and dummy symptoms (pain in 
legs, yellow vision). Participants were asked to score these items from 0 (absent) to 6 (very 
severe). In addition, they were also asked to score to what extent they felt hypoglycaemic.
First experiment day 2:
Participants were re-admitted to the CRCN at 08:00 hours the next morning after an overnight 
fast. The brachial artery of the non-dominant arm was cannulated (Angiocath 20-gauche; 
Deseret Medical, Sandy, UT, USA) under local anaesthesia (xylocaine 2%) for infusion of 
salbutamol and continuous blood pressure monitoring. An indwelling catheter was inserted 
into the antecubal vein of the contralateral arm for infusion of isoprenaline. Intra-arterial 
infusion rates of salbutamol were calculated per 100 ml forearm volume, measured by water 
displacement. After cannulations, a 30-min equilibration period was allowed to pass before 
baseline variables were obtained. Subsequently, 5-min infusions of saline and incremental 
doses of salbutamol (Ventolin; GlaxoSmithKline, Zeist, the Netherlands) diluted in a saline 
vehicle (0.003, 0.01, 0.03, 0.1, 0.3, 1.0 µg/min per 100 ml of forearm tissue) were administered 
intra-arterially (24). Forearm blood flow (FBF) was measured during the final 2 min of each 
dosing step in both arms, using ECG-triggered mercury-in-silastic strain gauge venous 
occlusion plethysmography as described previously (25). Wrist cuffs inflated to 220 mmHg 
eliminated the hand circulation during FBF measurements (26). The successive salbutamol 
doses were interrupted once by a 15-min drug-free interval for deflation of the wrist cuffs to 
allow recovery of hand circulation. The mean of eight FBF measurements was used for data 
analysis.
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Thirty minutes after the FBF measurements, the isoprenaline sensitivity test was carried 
out (15, 27). Participants were connected to a computer-assisted ECG (Fysioflex System, 
Nijmegen, the Netherlands) for determination of the heart rate response. Intra-arterial blood 
pressure was also recorded. Isoprenaline (Pharmacy department, University Medical Centre 
Groningen, the Netherlands) diluted in saline was injected intravenously as a 5 ml bolus 
infusion in incremental doses of 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0 and 4.0 μg or until the 
heart rate increased by >25 bpm. Each dose was given 2 min after the heart rate had returned 
to baseline level (approximately 5 min after the previous injection). The basal heart rate was 
defined as the mean heart rate for the 20 s before the first injection. The maximal heart rate 
was usually reached approximately 30-60 s following each injection. The maximal heart 
rate was determined as the mean of the three shortest consecutive RR intervals following 
each injection. Beta-adrenergic sensitivity was expressed as the dose of isoprenaline that 
increased the heart rate by 25 bpm over baseline values (IC25) (15).
Analytical procedures
After genomic DNA isolation from blood (28), genotyping of the A/G (rs1042713) polymorphism 
in ADRB2 was performed by pyrosequencing (29) according to the manufacturer’s protocol 
(Pyrosequencing, Uppsala, Sweden). Further details are provided in the Electronic 
supplementary material.  
The total symptom score was calculated separately for each category at each time point. The 
means of the scores obtained during the morning and afternoon clamp were used for analysis. 
Blood samples for glucose measurements were centrifuged immediately. Arterialised blood 
for determination of catecholamines, insulin, glucagon and cortisol was kept on ice before 
centrifugation and then stored at -80oC for later analysis. Plasma adrenaline (epinephrine) 
and noradrenaline (norepinephrine) were analysed by HPLC with fluorometric detection, 
as described previously (30). Plasma insulin was assessed by RIA using a human insulin 
standard (Novo Biolabs no 471), plasma glucagon was measured by competitive RIA using 
a reagent kit from Eurodiagnostica (Malmö, Sweden) and plasma cortisol was measured by 
Luminescence Immunoassay on an Architect random access analyser (Abbott, Hoofddorp, 
the Netherlands) (31). The final two measurements during the morning clamps (i.e. t=105 and 
t=165 min) and the afternoon clamps (i.e. t=390 and t=450 min) were averaged for analysis. 
Second experiment day 1 and day 2:
With an interval of at least 3 weeks, all subjects returned for the second set of experiments. 
Participants who underwent a euglycaemic clamp on day 1 of the first experiment underwent 
a hypoglycaemic clamp on day 1 of the second experiment and vice versa. Procedures of 
days 1 and 2 were similar to those described above for the first experiment
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Data analysis and statistical procedure
To detect differences in beta2-adrenergic sensitivity between the hypoglycaemia and 
euglycaemia study arms (as measured by quantifying the forearm vasodilator response to 
salbutamol infusion), we calculated that a sample size of eight participants was required 
to reach a power of 80% to find a 25% difference at a two-sided significance level of 5%. 
Statistical analyses were performed using SPSS (software package 16.0). Differences in the 
means of continuous measurements were tested by two tailed Student’s t test. Vasodilator 
responses to salbutamol were expressed as absolute FBF. The effect of salbutamol on 
FBF was analysed by repeated-measures ANOVA. The IC25 was determined by calculating 
sigmoidal dose-response curves for each participant using Graphpad software (version 4.02). 
The IC25 levels following euglycaemia and hypoglycaemia were compared with paired or 
independent Student’s t tests as appropriate. p < 0.05 was considered statistically significant. 
Data are presented as means ± SEM.
Results
Insulin, glucose, glucose infusion rate and counterregulatory hormones during the clamps: 
Mean plasma glucose levels were 4.9 ± 0.1 and 4.7 ± 0.0 mmol/l during morning and afternoon 
euglycaemia, respectively, vs 2.9 ± 0.1 and 2.9 ± 0.1 mmol/l during corresponding morning 
and afternoon hypoglycaemia (Figure 1). 
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Figure. 1 Plasma glucose values during the clamps on day 1 (above) and hypoglycaemic symptom scores during 
morning and afternoon clamps (below) in the whole group (n=16). White circles, hypoglycaemia; black circles, 
euglycaemia 
Insulin levels were similar during morning and afternoon euglycaemic and hypoglycaemic 
clamps (Table 1). Glucagon, adrenaline and cortisol responses were all significantly increased 
during both episodes of hypoglycaemia (Table 1). 
The glucagon response to afternoon hypoglycaemia was significantly attenuated compared 
with the response to morning hypoglycaemia. No significant differences in insulin levels, 
glucose levels, glucose infusion rate and counterregulatory hormone levels were observed 
between participants ArgArg and GlyGly or between males and females. 
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Table 1 Plasma hormone and glucose levels and glucose infusion rate during morning and afternoon glucose clamps
Measurement Euglycaemia Hypoglycaemia
Morning Afternoon Morning Afternoon
Glucose (mmol/l) 4.9 (0.1) 4.7 (0.1) 2.9 (0.1)a 2.9 (0.0)a
GIR (µmol kg-1 min-1) 38.1 (1.1) 43.8 (1.2) 9.4 (1.7)a 6.9 (1.6)a
Insulin (pmol/l) 547 (28) 580 (47) 524 (40) 564 (60)
Glucagon (pmol/l) 22.4 (0.9) 20.1 (0.6) 47.4 (5.6)a 32.8(3.5)ab
Cortisol (µmol/l) 0.32 (0.03) 0.27 (0.04) 0.65 (0.04)a 0.63 (0.05)a
Adrenaline (nmol/l) 0.18 (0.02) 0.20 (0.04) 2.93 (0.40)a 2.62 (0.27)a
Noradrenaline (nmol/l) 1.37 (0.14) 1.32 (0.15) 1.64 (0.78) 1.78 (0.19)
Values are means (SEM)
ap<0.05 compared with euglycaemia; bp<0.05 compared with morning experiment
GIR, glucose infusion rate
Day 1 hypoglycaemic symptoms
Total hypoglycaemic symptom scores in the whole group were low during both morning and 
afternoon euglycaemia, and did not differ between ArgArg and GlyGly participants (Figure 
2). During hypoglycaemia, scores were approximately six-fold higher, but did not differ 
between morning and afternoon hypoglycaemia, respectively, or between ArgArg and GlyGly 
participants. When adrenergic symptoms were analysed separately, there were no significant 
differences between morning and afternoon hypoglycaemia, or between ArgArg and GlyGly 
participants (data not shown).
Day 2 vasodilator response to salbutamol 
In response to salbutamol, FBF significantly increased following both euglycaemia (from 1.9 
± 0.15 ml min-1 100ml-1 to 11.9 ± 1.4 ml min-1 100ml-1) and hypoglycaemia (from 2.2 ± 0.22 ml 
min-1 100ml-1 to 16.2 ± 1.5 ml min-1 100ml-1) with the increase tending to be greater following 
hypoglycaemia (p=0.078, ANOVA, data not shown). This would be consistent with increased 
beta2-adrenergic receptor sensitivity following hypoglycaemia. This tendency towards 
increased beta2-adrenergic receptor sensitivity was driven by a significant increase in beta2-
adrenergic sensitivity after antecedent hypoglycaemia in ArgArg participants, with a maximal 
response to salbutamol of 18.6 ± 2.3 ml min-1 100ml-1 following hypoglycaemia and 12.2 ± 
2.0 ml min-1 100ml-1 following euglycaemia (p=0.019, ANOVA, Figure 2a), whereas no such 
effect was observed in GlyGly participants (Figure 2b). Heart rate and mean arterial pressure 
remained unchanged until the final and highest dose of salbutamol was infused, when both 
increased, suggestive of systemic effects (data not shown). 
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Figure 2. Response of FBF to salbutamol following antecedent hypoglycaemia and antecedent euglycaemia in 
(a) Arg16Arg participants (n=8, p=0.019) and (b) Gly16Gly participants (n=8, p=NS). White squares, hypoglycaemia; 
black squares, euglycaemia
Day 2 isoprenaline test
Two ArgArg and two GlyGly participants were excluded because of a technical error with 
the isoprenaline test or because the required heart rate response could not be reached, or 
was already reached with the lowest dose of isoprenaline. In the remainder (n=12), the IC25 
measured after day 1 euglycaemia was higher in ArgArg participants than in GlyGly participants 
(1.57 ± 0.25 μg vs 0.65 ± 0.14 μg, p=0.008). In response to two bouts of hypoglycaemia, the 
IC25 tended to decrease in ArgArg participants, suggestive of increased beta-adrenergic 
sensitivity, whereas the opposite was seen in GlyGly participants. This diverging response to 
isoprenaline (the response following euglycaemia minus hypoglycaemia for both genotypes) 
following hypoglycaemia between the two subgroups was statistically significant (p=0.047, 
Figure 3).
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Figure 3. IC25 following antecedent hypoglycaemia and antecedent euglycaemia in Arg16Arg participants (n=6, 
p=0.109) and Gly16Gly participants (n=6, p=0,193). The difference in IC25 between Arg16Arg and Gly16Gly participants 
(IC25 following antecedent euglycaemia minus antecedent hypoglycaemia for each subgroup): p=0.047
Discussion
In the present study, two episodes of hypoglycaemia, a stimulus sufficient to impair next day 
counterregulatory responses and hypoglycaemic awareness in healthy participants (4, 5), did 
not decrease beta2-adrenergic sensitivity in either participant subgroup. In contrast, beta2-
adrenergic sensitivity significantly increased following hypoglycaemia in participants who 
were homozygous ArgArg for the beta2-adrenergic receptor, but did not change in those who 
were homozygous GlyGly. Analogously, hypoglycaemia induced an increase in overall beta-
adrenergic sensitivity measured with the isoprenaline test in ArgArg participants relative to 
the GlyGly participants. These findings suggest differences by genotype in the capacity to 
adapt to repeated hypoglycaemia.
Our finding of increased rather than reduced beta2-adrenergic sensitivity after antecedent 
hypoglycaemia argues against a direct role for reduced beta2-adrenergic sensitivity in the 
pathogenesis of hypoglycaemia unawareness. This seems at odds with studies reporting 
reduced overall beta-adrenergic sensitivity in type 1 diabetic participants with hypoglycaemia 
unawareness (14, 16-18, 32) or healthy participants following hypoglycaemia (15, 21). However, 
in contrast to these studies, we used a well-validated model for hypoglycaemia unawareness 
(5) and studied healthy participants rather than type 1 diabetic patients. In fact, the only other 
study that used a comparable approach reported that a single nocturnal hypoglycaemic 
episode increased next morning beta-adrenergic sensitivity in healthy participants, whereas 
it decreased in patients with type 1 diabetes (15). The authors interpreted this increase in 
beta-adrenergic sensitivity as a compensatory response to prevent future hypoglycaemia, 
an adaptive process that was apparently lost or exhausted in patients with type 1 diabetes. 
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Our data raise the intriguing question as to whether the disparate responses to antecedent 
hypoglycaemia in the two genotype subgroups translate into a different susceptibility to 
developing hypoglycaemia unawareness in patients with type 1 diabetes. As mentioned 
above, one previous study has reported increased overall beta-adrenergic sensitivity after 
hypoglycaemia in healthy non-diabetic participants (15). Our findings are in accordance with 
these data insofar that the increase in beta2-adrenergic sensitivity was limited to the ArgArg 
participants. This increase in beta2-adrenergic sensitivity is potentially protective against future 
hypoglycaemic events. Conversely, GlyGly participants, who appear to lack this protective 
response, may be more prone to hypoglycaemic events and the subsequent development of 
hypoglycaemia unawareness. Although we realise that findings in healthy participants cannot 
be automatically translated to diabetic individuals, we speculate that this observation could 
potentially explain the association between hypoglycaemia unawareness and the GlyGly 
polymorphism for the beta2-adrenergic receptor in type 1 diabetic patients (10). 
Overall beta-adrenergic sensitivity, following antecedent euglycaemia as reflected by the 
response to isoprenaline, appeared lower in ArgArg participants than in GlyGly participants, 
but tended to increase in ArgArg participants and to decrease in GlyGly participants following 
antecedent hypoglycaemia. However, although the effect of antecedent hypoglycaemia on 
overall beta-adrenergic sensitivity in ArgArg participants was consistent with the effect on 
beta2-adrenergic sensitivity, these data should be interpreted with caution. First, the time 
between the second hypoglycaemic episode on day 1 and the isoprenaline experiment on 
day 2 was at least 18 h, which is longer than in other studies where beta-adrenergic sensitivity 
was measured either directly (21) or within ~10 h after the hypoglycaemic event (15). 
Second, the isoprenaline test was performed shortly after beta2-adrenergic sensitivity was 
assessed with salbutamol. Systemic effects of the final salbutamol dose could therefore have 
interfered with the subsequent isoprenaline test. Since beta2-adrenergic sensitivity was the 
primary outcome, we deliberately chose to perform the isoprenaline test afterwards, whereas 
repeating the entire clamp procedure for this purpose was regarded as too great a burden for 
our healthy participants. Third, since we had to exclude four participants from the analysis, 
we may have simply lacked the power to show meaningful effects. Finally, our observation 
that the differences in beta-adrenergic sensitivity between the two genotype subgroups only 
applied to the euglycaemic experiments may indicate a baseline difference in adrenergic 
sensitivity or may reflect a general inaccuracy of the test method without clinical relevance.
One other limitation that deserves comment is that we did not formally test that 
hypoglycaemia unawareness was induced on day 2. However, others have repeatedly shown 
that two hypoglycaemic events are sufficient to impair counterregulatory hormone responses 
to and symptomatic awareness of next-day hypoglycaemia (4-6). Furthermore, there was 
a reduced glucagon response compared with the preceding morning’s hypoglycaemia, 
indicating impending counterregulatory impairment. 
73
Ch
ap
te
r 4
Chapter 4 | Effect of  hypoglycaemia on beta2-adrenergic sensitivity
In conclusion, antecedent hypoglycaemia increased beta2-adrenergic sensitivity in young 
healthy participants ArgArg for ADRB2 in contrast to GlyGly participants who did not show 
increased beta2-adrenergic sensitivity. We propose that non-diabetic participants ArgArg 
for ADRB2 may to some extent be protected against the development of some aspects of 
hypoglycaemia unawareness, but that GlyGly participants lack this protective mechanism. 
Further research, especially in diabetic participants, is necessary to explore this hypothesis. If 
this is confirmed in the type 1 diabetic population, it may help physicians to better anticipate 
the risk of developing hypoglycaemia unawareness when pursuing optimal glycaemic 
control. 
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Eﬀ ect of sex on the cardiovascular response 
to adrenaline in humans
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Abstract
Cardiovascular responsiveness to stress conditions differs between men and women. It is 
not known to what extent this observation is explained by differences in the release of stress 
hormones like adrenaline, or by differences in the response to adrenaline. Therefore, we 
quantified the hemodynamic response to infusion of adrenaline (0.04, 0.06, and 0.08 µg·kg-
1·min-1 for 20 minutes each) in 8 healthy men and 8 healthy women in a randomised placebo-
controlled cross-over design. Arterial plasma adrenaline levels were measured before and 
after infusion. Heart rate and intra-arterial blood pressure were monitored throughout the 
experiment. Arterial plasma adrenaline levels increased similarly in both sexes. There was a 
larger increase in systolic blood pressure in women compared to men (17.6 ± 3.1 vs 5.1 ± 2.8 
mmHg, P<0.01). In contrast, men showed a larger increase in heart rate compared to women 
(20.3 ± 1.4 vs 11.2 ± 2.8 bpm, P<0.01). 
We concluded that adrenaline showed a predominant alpha-adrenergic response in women, 
causing a larger increase in systolic blood pressure. In contrast, men showed a larger beta-
adrenergic response causing a decline in diastolic blood pressure and a more pronounced 
increase in heart rate. 
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Introduction
The incidence of cardiovascular diseases and hypertension is lower in premenopausal 
women (1). A concurrent observation is that cardiovascular responses to a variety of stressors 
also differ between men and women. For instance, the cold pressor test causes a larger 
increase in systolic blood pressure in men than in women (2) whereas hypoglycaemia causes 
larger increases in both systolic blood pressure and heart rate in men compared to women 
(3). In analogy, the stress-induced release of vasoactive catecholamines may differ between 
men and women, with women usually exhibiting a much smaller adrenaline release (3, 4). 
In these stress conditions, release of adrenaline is an important effector mechanism which 
acts through alpha- and beta-adrenergic receptors on the myocardium and vessel wall. 
The magnitude by which endogenous adrenaline levels increase may range from 3-5-
fold (during exercise) to >30-fold (during hypoglycaemia). It is generally assumed that the 
different cardiovascular response to stress in men and women is at least partly the result of 
differences in the release of catecholamines, adrenaline. Some studies also report differences 
in the response to catecholamines. Several in vitro and in vivo studies that reported gender 
differences in cardiovascular responses to various adrenergic agonists (5-7) indicate a 
contribution of dissimilar sensitivity in response to adrenaline. However, gender differences 
in the integrated response to the endogenous stress hormone adrenaline, especially at 
high concentrations, are not known. Therefore, the aim of our study was to investigate the 
difference in cardiovascular response between men and women to adrenaline infusion in a 
dosage comparable with a very potent stressor. 
Methods
Subjects
We studied 8 non-smoking males and 8 non-smoking premenopausal females, matched for 
age and body-mass. These subjects also participated in a previous study on hypoglycaemia 
unawareness (8). All subjects were healthy and did not use any medication other than oral 
contraceptives. The study was performed as a placebo controlled single blind cross over 
design and was approved by the medical ethics committee of the Radboud University 
Nijmegen Medical Centre. Written informed consent was obtained before participation. 
Subjects were studied on two occasions, at least 3 weeks apart. Female subjects were studied 
at exact 4-wk intervals to ensure that experiments were performed during corresponding 
periods of the menstrual cycle. 
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Experimental design
Each participant was admitted to the research unit at 0800 h, having abstained from alcohol 
and caffeine respectively for 24 h and 48 h. Under local anaesthesia (Xylocaine 2%), the brachial 
artery of the nondominant arm was cannulated (Angiocath 20-gauge, Becton Dickinson, 
Sandy, UT) for blood sampling and for hemodynamic monitoring (Monitor 378341A, Hewlett-
Packard GmbH, Boeblingen, Germany). The antecubital vein of the contra-lateral arm was 
cannulated for administration of adrenaline (International Medication Systems Ltd., Slough, 
UK) or placebo (NaCl 0.9%) infusions. After a 30-min equilibration period, blood was sampled 
for baseline measurements. Thereafter, adrenaline or an equivalent volume of saline was 
administered intravenously at an initial rate of 0.04 µg·kg-1·min-1 for 20 min, followed by 0.06 
and 0.08 µg·kg-1·min-1 for another 20 min each (total amount, 3.6 µg·kg-1 body weight over 60 
min). Target plasma adrenaline levels were 6–9 nmol·liter-1 in order to mimic a potent stressor. 
Heart rate and intra-arterial blood pressure were monitored throughout the experiment. 
Statistical analysis
Serial data were compared between groups by repeated measures ANOVA and differences 
in means were tested using paired Student’s t test. For calculations and statistical analyses, 
the SPSS personal computer software package (SPSS, Chicago, IL) was used. P < 0.05 was 
considered statistically significant. Results in figures are expressed as means ± SEM, unless 
otherwise indicated.
Results
At baseline, the systolic and diastolic blood pressure (BP) were similar in men and women, 
heart rate was higher in women (69 ± 3 vs 60 ± 2 bpm, P=0.04). Conversely, baseline arterial 
plasma adrenaline levels were slightly higher in males compared to females (0.13 ± 0.02 vs 0.08 
± 0.01 nmol/l, P=0.04). After adrenaline infusion, plasma adrenaline levels increased similarly 
in men and women (7.84 ± 0.46 vs. 8.23, ± 0,58 p=NS). Almost equal plasma concentrations 
of adrenaline were achieved after adrenaline infusion in men and women (7.96 ± 0.47 vs 8.31 
± 0.58 nmol/l, P=NS), comparable with those attained under hypoglycaemic conditions (8). 
When compared to placebo, adrenaline infusion caused a dose-dependent increase in heart 
rate in both men and women, but the increase was significant larger in men (20.3 ± 1.4 vs 
11.2 ± 2.8 bpm, P<0.01). In contrast, systolic BP rose significantly more in women than in men 
during adrenaline infusion (17.6 ± 2.8 vs 5.1 ± 3.1 mmHg, P<0.01). The diastolic BP tended to 
decrease more in men compared to women although this difference did not reach statistical 
significance (10.1 ± 1.8 vs 5.2 ± 2,6 mmHg, P=NS). (Figure 1). As a consequence, MAP decreased 
in men but not in women after adrenaline infusion (P=0.05 for the difference between men 
and women, data not shown)
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Figure 1. Mean changes in systolic and diastolic blood pressure and heart rate during adrenaline infusion in men 
and women. Data are presented as mean± SEM
* = P<0.05,  NS=Not Significant
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Discussion 
The present study was conducted to compare the cardiovascular effects of adrenaline in 
men versus women. We observed a remarkable gender difference in the response to elevated 
adrenaline levels. In men, adrenaline caused a substantial rise in heart rate and a moderate 
rise in systolic BP. In contrast, women exhibited the reverse response: a substantial rise in 
systolic BP and a moderate rise in heart rate. Although baseline plasma adrenaline levels 
were slightly lower in women, similar levels were obtained after exogenous administration. 
In contrast to our observation, Lenders et al. (9) reported that infusion of adrenaline resulted 
in lower plasma adrenaline levels in women than men, possibly as a result of lower clearance 
rates. After correction for plasma adrenaline levels, they found similar cardiovascular 
responses to adrenaline infusion. In their study,  plasma adrenaline levels were obtained 
from venous blood samples while we measured arterial blood samples. The latter are known 
to be more accurate because the extraction of adrenaline across the forearm skeletal muscle 
vascular bed may be as high as 51% (10). In our study, rather high doses of adrenaline were 
used, comparable with very potent stressors like a hypoglycaemic event. This difference in 
adrenaline dose may also account for the different conclusions of both studies.   
Adrenaline interacts with alpha-, beta1- and beta2-adrenergic receptors, the stimulation 
of which depends on the plasma concentration. At low plasma concentration, adrenaline 
primarily stimulates beta-adrenergic receptors, leading to increased heart rate (beta1) and 
peripheral vasodilation (beta2). At higher concentrations, alpha-adrenergic activity starts 
to prevail causing increased vascular tone and increased blood pressure. Indeed, in men 
the lowest adrenaline dose caused the heart rate to increase and diastolic BP to decrease, 
whereas systolic BP remained unchanged. In women, however, systolic BP already increased 
in response to the lowest adrenaline infusion, whereas diastolic BP did not change. These 
responses are consistent with increased alpha-adrenergic and decreased beta2-adrenergic 
sensitivity in women compared to men. Previous human and animal studies also suggested 
increased alpha-adrenergic sensitivity in premenopausal women (5, 6). 
Our conclusion on a reduced beta2-adrenergic sensitivity in women does not agree with an 
elegant study of Kneale et al. In that study, the forearm vasodilator response to intra-arterial 
albuterol was larger in women (7). Of course, this discrepancy may be explained by the 
different study method because the intra-arterial infusion approach implies that the effects 
of albuterol are limited to the forearm skeletal muscle vascular bed. Moreover, differences 
in dosing may also explain the discrepancy. In our study, the highest adrenaline dose also 
produced a fall in diastolic BP in women that approximated that observed in men. 
The higher heart rate response to adrenaline in men is compatible with a more pronounced 
cardiac beta1-adrenergic receptor sensitivity. However, considering the larger decrease in 
diastolic blood pressure, baroreflex mediated heart rate increase seems a more plausible 
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explanation. Moreover, previous studies have shown a more pronounced baroreflex response 
in men compared to women (11, 12). 
In summary, adrenaline affects the cardiovascular system differently in men and women, 
with beta2-(and possibly beta1-) adrenergic activity prevailing in men (reduced vascular 
tone and increased heart rate) and alpha-adrenergic activity prevailing in women (increase 
in systolic blood pressure). In men greater baroreflex sensitivity might have contributed to 
the profound heart rate increase in response to adrenaline. To what extent the observed 
disparate response is cardioprotective for women requires further research. 
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Abstract
Objective
It is likely that impaired awareness of hypoglycaemia (IAH) and severe hypoglycaemia are 
in part determined by genetic factors. The aim of this study was to investigate candidate 
genes for associations with IAH and severe hypoglycaemia in a cohort of patients with type 
1 diabetes (T1D).
Methods
Consecutive patients with T1D were genotyped for SNPs in or near the genes for the beta-1 
and beta-2 adrenergic receptor (ADRB1, ADRB2), SORCS1 and BNC2, and for the insertion/
deletion polymorphism in ACE gene. IAH and severe hypoglycaemia was assessed using a 
validated questionnaire. 
Results 
Out of 486 patients, 32.5% were classified as having IAH. The Arg16Gly polymorphism of 
ADRB2 was associated with IAH: OR 1.49 (CI 1.01-2.20, p=0.046) Gly16 (GG) versus carriers 
of the A allele. In a haplotype analysis, the association was highest in patients with GG at 
position 16 and heterozygous at position 27 (OR2.19, CI 1.33-3.61, p=0.03). There were no 
associations between IAH and other genes, and none of the studied genes were associated 
with severe hypoglycaemia.  
Conclusions
Genotypes at two variants of ADRB2 are associated with IAH. This association is comparable 
with the risk of classical risk factors for IAH. 
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Introduction
Impaired awareness of hypoglycaemia (IAH), defined as absence of appropriate autonomic 
warning symptoms before the onset of neuroglycopenia, is the clinical representation of 
a habituation process to recurrent hypoglycaemia that considerably increases the risk of 
(severe) hypoglycaemia (1). Various cohort studies have shown that IAH affects approximately 
25% of patients with type 1 diabetes (2-5). Remarkably, this proportion has remained 
relatively stable over time, despite advances in insulin replacement therapy (e.g. insulin 
analogues and subcutaneous pumps) and glucose monitoring (e.g. glucose sensors) aimed 
at reducing the burden of hypoglycaemia. Although the role of antecedent hypoglycaemia in 
the development of IAH is undisputed, the underlying pathophysiological mechanisms are 
incompletely understood.
Most clinical risk factors for IAH relate to the (antecedent) hypoglycaemia event rate and 
the integrity of counterregulatory function. These risk factors include a history of recurrent 
(nocturnal) hypoglycaemia, low HbA1c, absence of C-peptide and duration of diabetes (6). 
Given the relative stability of its prevalence over time, it is questionable whether clinical risk 
factors alone explain the entire problem of IAH in people with type 1 diabetes. Many patients 
with type 1 diabetes suffer from recurrent hypoglycaemic events, but not all of them develop 
IAH as a result of that. Indeed, IAH may be present in patients with poor glycaemic control, 
whereas patients with near-normal glycaemic control may still report normal awareness 
of hypoglycaemic episodes. This suggests the presence of a genetic predisposition for the 
development of IAH.
We previously found that a polymorphism in the gene encoding the β2-adrenergic receptor 
(ADRB2), which predicts greater vulnerability to agonist-driven reductions in β-adrenergic 
sensitivity (7) was associated with IAH in a small cohort of patients with type 1 diabetes (8). 
Reduced β-adrenergic sensitivity may impair hypoglycaemia-induced counterregulation (9, 
10) and has been observed in patients with IAH (11-14), but not by all (15). Two other single 
nucleotide polymorphisms (SNPs) in ADRB2 have been related to receptor desensitization 
upon chronic stimulation (7, 16) and there is linkage disequilibrium between the SNP’s of 
ADRB2 so a haplotype analysis is warranted. Potential genetic predisposition for developing 
severe hypoglycaemia, the principal complication of IAH, has also been reported (17, 18). 
A genome-wide association study (GWAS) performed on the DCCT type 1 diabetes cohort 
showed that variants near SORCS1 (rs1358030) and BNC2 (rs10810632) that were associated 
with HbA1c were also associated with the occurrence of severe hypoglycaemia, albeit only 
in patients randomized to the conventional treatment arm of the trial (17). The commonly 
studied insertion/deletion polymorphism of the ACE genotype (rs4646994), which results 
in high serum ACE activity, was associated with severe hypoglycaemia events in a Danish 
cohort of patients with type 1 diabetes (18), but not in an Australian cohort of children with 
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type 1 diabetes (19). The ACE polymorphism was not associated with IAH in neither cohort 
where this was studied (20, 21). 
In this study, we aimed to explore all previously studied genetic factors for an association with 
IAH in a contemporary cohort of patients with type 1 diabetes. Furthermore, we investigated 
potential associations of these genotypes with severe hypoglycaemia in the past year. 
Methods
Participants
This study was performed in a prospective cohort of patients with type 1 diabetes. Participants 
were included in this cohort from 2006-2008 and recruited from the outpatient diabetes clinic 
of the Radboud university medical center. The local ethics committee approved the study. 
All patients had to be classified as having type 1 diabetes according to their physician and 
provided written informed consent. During a routine visit to the clinic, blood was drawn for 
DNA isolation and storage. All patients completed a questionnaire to identify IAH status (see 
below). Clinical data were collected from the patient’s charts. 
Genotyping 
DNA was extracted from whole blood using salt extraction (22). Genetic analyses were 
performed in a CCKL (Co-ordination Committee for the promotion of Quality Control with 
regard to Laboratory research, www.cckl.nl)-accredited laboratory at the department of 
Human Genetics of the Radboud university medical center in Nijmegen, The Netherlands.
Genotyping of the SNPs was performed using Taqman SNP genotyping assays according 
to the manufacturer’s protocol (Life Technologies, Bleiswijk, Netherlands rs1042713 
ADRB2 ARG16GLY (A46G) assay ID C___2084764_20, rs1042714 ADRB2 Gln27Glu C79G 
assay ID C___2084765_20, rs1800888 ADRB2 Thr164Ile (C491T) assay-ID C___8950503_20, 
rs1801252 ADRB1 Ser49Gly (A145G) assay ID C___8898508_10,  rs1801253 ADRB1 Arg369Gly 
(G1165C) assay ID C___8898494, rs10810632 BNC2 assay ID C__31294328 and rs1358030 
SORC1  C__9593567. Signals were detected with the 7500 Fast Real-Time PCR system (Life 
Technologies) and subsequently analysed using the Allelic Discrimination software version 
1.4 (Life Technologies). Five percent of the samples were analysed in duplicate.
The insertion/deletion (indel, rs4646994) polymorphism in the ACE gene was assessed using 
two independent PCR amplifications, one which amplified both the I and D alleles (forward 
primer 5’- GGGACTCTGTAAGCCACTGC -3’ and reverse primer 5’-CCATGCCCATAACAGGTCTT -3’) 
and one insertion-specific PCR (forward primer 5’- TGGGACCACAGCGCCCGCCACTAC-3’ and 
reverse primer 5’-TCGCCAGCCCTCCCATGCCCATAA-3’), using taq DNA polymerase (InvitrogenTM, 
Life Technologies) and a PCR buffer with 10 mM Tris-HCl pH 9.0, 50 mM KCl, 1.5 mM MgCl2 and 
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0.01% (w/v) gelatine. Annealing temperatures: 60°C for the detecting of the I and D alleles and 
70°C for the insertion specific PCR. Size fractionation and visualization was performed by gel 
electrophoresis. Three samples of each genotype were sequenced as quality control.
Assessment of IAH status
All patients completed a Dutch translation (23) of the Clarke questionnaire (24), which has 
been validated for detecting IAH. The questionnaire consists of 5 items, each of which can 
be scored by either 0 or 1 point, and relate to the presence (or absence) of symptoms during 
hypoglycaemia, the glucose level below which the patient recognizes these symptoms 
as hypoglycaemic, and the number of moderate hypoglycaemia in the past month and 
of severe hypoglycaemia in the past year.  For calculation purposes, the total scores were 
dichotomized, so that patients with a score of 3 or above were considered to have IAH and 
those with lower scores to have retained sufficient hypoglycaemic awareness. 
Statistics
Statistical analysis was performed using SPSS software package for windows, version 19.0.0 
(SPSS, Chicago, IL USA). Genotype frequencies were tested for Hardy-Weinberg equilibrium 
(HWE). A dominant model was used for the genetic analysis (comparison of the most frequent 
homozygous genotype versus carriers of the less frequent allele). These analyses were 
performed using Chi-square tests. Differences in the means of continuous measurements 
were tested by two-tailed Student’s t-test. Risk was estimated by the Odds ratios (OR) and 
their 95% confidence intervals (95% CI). As this study is a replication of previously reported 
association we considered a p-value of 0.05 as statistically significant.
A logistic regression analysis was performed to correct for classical risk-factors for 
hypoglycaemia unawareness. Haplotype frequencies and linkage disequilibrium (LD) were 
calculated using PLINK. 
Results
A total of 491 patients gave informed consent for DNA analysis and filled out the questionnaire. 
486 Patients were adequately genotyped and included in the analysis. From 5 patients, no 
adequate DNA analysis could be performed (no sample or conformation-test failure). The 
majority of the patients were Caucasian of origin. 
Baseline characteristics
In Table 1, demographic data are severe shown according to awareness status and history of 
severe hypoglycaemia. A total of 158 patients (33%) were classified as having IAH. Patients with 
IAH were significantly more frequent male, were older, had a longer duration of diabetes and had 
better glycaemic control than those with normal IAH. The prevalence of autonomic neuropathy 
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and estimated GFR below 60 ml/min/1.73 m2 was also higher among these patients. 103 
Patients (21%) recalled experiencing at least one severe hypoglycaemic event in the past year, 
75% of whom could be classified as being hypoglycaemia unaware. severe hypoglycaemia 
was associated with autonomic neuropathy, but not with HbA1c or other risk factors for IAH 
(Table 1). Patients with IAH were at almost 12-fold greater risk of having experienced severe 
hypoglycaemia than those with normal hypoglycaemic awareness (data not shown).  
Table 1: Clinical characteristics of participating patients according to hypoglycaemia awareness status and 
occurrence of severe hypoglycaemia. 
N (%)
Aware 
328 (67)
IAH
158 (33)
No severe Hypo
383 (79)
Severe Hypo
103 (21)
Male sex (%) 143 (44) 84 (53)* 178 (47) 49 (48)
Age (years) 44 ± 14 48 ± 13* 46 ± 14 45 ± 14
Duration of diabetes (years) 24 ± 13 29 ± 12** 25 ± 13 26 ± 12
BMI (kg·m-2) 26.1 ± 4.2 25.9 ± 4.4 26.2 ± 4.1 25.5 ± 4.9
HbA1c (%) 8.1 ±1.3 7.7 ±1.0** 8.0 ± 1.2 7.9 ± 1.1
Multiple daily subcutaneous injections, short and 
long acting insulin (%)
218 (68) 105 (67) 256 (68) 67 (65)
Twice daily subcutaneous injections, premixed 
insulin (%)
8       (3) 5       (3) 9       (2) 4      (4)
Continuous subcutaneous insulin infusion, CSII (%) 96   (30) 48   (30) 112 (30) 32   (31)
Retinopathy (%) 141 (45) 68   (44) 161 (43) 48   (48)
Peripheral neuropathy (%) 109 (34) 66   (43) 134 (36) 41   (41)
Autonomic neuropathy (%) 14    (4) 15   (10)* 16     (4) 13   (13)†
Nephropathy (%) 67   (25) 34   (25) 75   (24) 26   (29)
MDRD <60ml/min/1.73m2 (%) 7      (2) 12     (8)* 12     (3) 7      (7)
Macrovascular complications (%) 41   (3) 27   (17) 48   (13) 20   (19)
Data are presented as number or mean (± SD).
* indicates P<0.05, and ** P<0.0001 versus IAH † indicates P<0.05 versus No SH.
Genetic analysis
All genotypes tested were in HWE. The p-values for HWE of the SNPs were: rs1042713 p=0.34, 
rs1042714 p= 0.17, rs1800888 p= 0.77, rs10810632 p=0.45, rs1358030 p=0.91, rs1801252 
p=0.14, rs1801253 p=0.69, rs4646994 p=0.77.  Tables 2 and 3 show the genetic analyses 
according to awareness status and history of severe hypoglycaemia, respectively. The 
Arg16Gly polymorphism of ADRB2 was associated with hypoglycaemia unawareness: 
patients homozygous Gly16 (GG) were 1.49 times more likely to have IAH than patients 
heterozygous Arg16Gly (AG) or homozygous Arg16 (AA): OR=1.49 (95% CI 1.01-2.20, P=0.046). 
In a logistic regression model, which includes known risk factors for IAH (gender, age, 
duration of diabetes, HbA1c) resulted in a similar odds ratio (OR=1.35, 95% CI:0.90-2.03) 
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indicating that the genetic association is largely independent of classical risk factors like 
male gender (OR=1.47, 95% CI 1.00-2.15), lower HbA1c (per 1%: OR=1.4, 95%CI:1.16-1.68) and 
duration of diabetes (per 10 years OR=1.30, 95% CI:1.20-1.50). Of the nine patients who were 
heterozygous Thr164Ile (CT), five (56%) had IAH compared to 153 out of 477 (32%) of those 
homozygous Thr164 (OR=2.63, 95% CI 0.70-10.0) but due to the low numbers this difference 
failed to reach statistical significance. IAH was not associated with any of the other SNPs of 
ADRB2. The LD between the SNPs at codon 16 and 27 is not complete, haplotype analysis 
was performed by combining these two variants. Six different haplotypes were found among 
the patients in our cohort (Supplementary table).  Patients with the Gly16Gly/Gln27Glu 
haplotype were at the highest risk of IAH (OR=2.19, 95%CI 1.33-3.61, P=0.03) compared to the 
other haplotypes. After inclusion of HbA1c, age, sex and duration of diabetes the haplotype OR 
only slightly changed OR=2.05 (95%CI 1.22-3.46). 
We found no evidence of an association between IAH and SNPs of SORCS1 BNC2 and ADRB1, 
or ACE indel (Tables 2 and 3). There were also no associations between any of the SNPs, 
including SNPs of the ADRB2 gene with a history of severe hypoglycaemia.
Table 2: genotype frequencies of participating patients according to hypoglycaemia awareness status. 
Genotype Aware
n (%)
IAH
n (%)
Odds ratio
(95% CI)
ADRB2: rs1042713 
GG
AA/AG 
ADRB2: rs1042714
CC
GG/CG  
ADRB2: rs1800888
CC
CT 
ADRB1: rs1801252
AA
GG/AG
ADRB1: rs1801253
CC
CG/GG
BNC2: rs10810632
TT 
TT/TC
SORCS1: rs1358030
TT
TC/CC
ACE I/D: rs4646994
DD 
ID/II  
114 (62.0)
214 (70.9)
101 (71.1)
227 (66.0)
324 (67.9)
4 (44.4)
261 (68.5)
67 (63.8)
175 (65.3)
153 (70.0)
279 (67.7)
46 (66.7)
134 (69.1)
194 (66.4)
82 (62.1)
241 (69.1)
70 (38.0)
88 (29.1)
41 (28.9)
117 (44.4)
153 (32.1)
5 (55.6)
120 (31.5)
38 (36.2)
93 (34.7)
65 (29.8)
133 (32.2)
23 (33.3)
60 (30.9)
98 (33.6)
50 (37.9)
108 (30.9)
1.49 (1.01-2.20)
0.79 (0.51-1.21)
0.38 (0.10-1.43)
0.81 (0.52-1.28)
1.25 (0.85-1.81)
0.95 (0.56-1.64)
0.89 (0.60-1.31)
1.35 (0.89-2.08) 
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Table 3: genotype frequencies of participating patients according to self-reported occurrence of severe 
hypoglycaemia over the past year  
Genotype No severe hypo
n (%)
Severe hypo
n (%)
Odds ratio
(95% CI)
ADRB2: rs1042713
 GG
 AA/AG  
ADRB2: rs1042714        
CC
CG/GG 
ADRB2: rs1800888 CC
CT
ADRB1: rs1801252
AA
AG/GG  
ADRB1: rs1801253
CC
CG/GG  
BNC2: rs10810632
TT
TC/CC
SORCS1: rs1358030
TT
TC/CC
ACE I/D: rs4646994
DD
II/ID
143 (77.7)
240 (79.0)
104 (73.2)
279 (81.1)
376 (78.8)
7 (77.8)
306 (80.3)
77 (73.3)
211 (78.7)
172 (78.9)
323 (78.4)
56 (80.0)
155 (79.9)
228 (78.1)
98 (74.2)
281 (77.4)
41 (22.3)
62 (31%)
38 (26.8)
65 (18.9)
101 (21.2)
2 (22.2)
75 (19.7)
28 (26.7)
57 (21.3)
46 (21.1)
89 (21.6)
13 (20.0)
39 (20.1)
64 (21.9)
34 (25.8)
68 (22.6)
0.90 (0.58-1.41)
1.57 (0.99-2.48)
0.94 (0.19-4.59)
0.67 (0.41-1.11)
1.01 (0.65-1.56)
1.19 (0.62-2.26)
0.90 (0.57-1.40)
1.43 (0.89-2.30)
Discussion
We assessed the contribution of genetic variants in candidate genes to the risks of IAH and 
severe hypoglycaemia in patients with type 1 diabetes. We showed that patients homozygous 
Gly16 (GG) were 1.49 times more likely to have IAH than patients heterozygous Arg16Gly (AG) 
or homozygous Arg16 (AA): OR=1.49 (95% CI 1.01-2.20, P=0.046). Patients with the Gly16Gly/
Gln127Glu (GG/CG) haplotype were at twofold greater risk for having IAH, while the risk for 
severe hypoglycaemia was not affected. The other candidate genes were neither related to 
IAH nor to a history of severe hypoglycaemia. 
This study confirms our previous results on the association between Gly16 homozygosity of 
ADRB2 and hypoglycaemia unawareness (8) although the small sample size of that study 
precluded haplotype analysis, which we now included. The effect size of the SNP at codon 
16 and of the Gly16Gly/Gln127Glu (GG/CG) haplotype of ADRB2 impacting on the risk of 
hypoglycaemia unawareness was at least comparable with that of the clinical risk factors 
Correction for these clinical risk factors only slightly modified the genetic association with 
IAH, which shows that the ADRB2 polymorphism independently predisposes to IAH. 
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Several ADRB2 polymorphisms have been implicated in increased vulnerability to agonist-
promoted receptor down regulation. Most in vivo data have found that substitution of 
glycine for arginine at codon 16 reduces sensitivity of the receptor upon chronic stimulation 
(25). Conversely, in our study subjects homozygous Arg16 were somewhat protected 
against the development of hypoglycaemia–induced receptor downregulation, whereas 
those homozygous Gly16 were not (9). Finally, the rare Thr164Ile polymorphism of ADRB2 
is particularly interesting as substitution of Isoleucine for Threonine leads to an important 
signalling defect with reduced affinity of the receptor for catecholamines (26). Homozygosity 
Ile164Ile is very rare and associated with hypertension (27).  The observation that more 
than half of the nine subjects heterozygous Thr164Ile (CT) had IAH further underscores the 
potential role of ADRB2 downregulation in the pathogenesis of IAH.
Polymorphisms of ADRB2 were unrelated to the incidence of severe hypoglycaemia, but this 
discrepancy is not unusual. Indeed, the DD genotype of ACE that was reported to predispose 
for severe hypoglycaemia in Danish patients with type 1 diabetes did not predispose for IAH 
in the same population (20). These observations may be explained by different pathways 
leading to severe hypoglycaemia or IAH. It is also plausible that patients with IAH to some 
extent display anticipatory behaviour to avoid severe hypoglycaemia. 
We found no evidence for an association between SNPs of any of the currently investigated 
candidate genes and the risk of severe hypoglycaemia, which is in accordance with findings 
of most others (19, 28). Some studies (17) have suggested a relationship. These contrasting 
findings may be due to differences in the populations studied, specifically the level of 
glycaemic control which is somewhat better in our cohort compared to some of the other 
cohorts studied. The closer that glucose control approaches normality, the stronger the 
contribution of insulin treatment, which may make it more difficult to identify a genetic 
component that could potentially affect the risk of (severe) hypoglycaemia (29). This 
paradoxical phenomenon explains how a GWAS on the DCCT population (17) could identify 
genetic factors correlated with severe hypoglycaemia in the conventional treatment group 
(average HbA1c, 9%), but not in the intensive treatment group (7%), despite a threefold higher 
incidence of severe hypoglycaemia in the latter (30, 31). In our cohort, the reasonable level of 
glycaemic control may thus have masked such a genetic contribution.
Our study has strengths and limitations. This is the first study that has investigated several 
genetic polymorphisms potentially related to presence of IAH and history of severe 
hypoglycaemia in a well-defined cohort of people with type 1 diabetes. We tried to include 
as many patients with type 1 diabetes from our outpatient department as possible. Although 
rather small for genetic studies this is one of the largest cohorts of patients with type 1 
diabetes investigating genetic involvement in awareness status. A power analysis shows 
that for IAH we had 80% power to detect a relative risk of 1.4 in a dominant model (allele 
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frequency of 0.35, with alpha 0.05). However, the 103 patients reporting SH in the past 
year were too low a number to detect a small genetic influence. No correction for multiple 
testing was performed because of the exploratory nature of the study. Another limitation 
concerns the assessment of IAH. We chose to use the Clarke questionnaire, because a Dutch 
translation of this questionnaire has been validated with hypoglycaemic glucose clamps 
(23) and because it correlates well with other validated checklists for IAH (32). Nonetheless, 
none of the methods used to assess IAH is fully reliable. In addition, for analytical reasons, 
the results were dichotomized, whereas ‘IAH’ is not a binary phenomenon and the level of 
awareness may vary over time within one person. Finally, data on severe hypoglycaemia 
were retrieved from the Clarke questionnaire, which may have introduced bias, although 
self-reporting of severe hypoglycaemic events in the past year has been shown to reliably 
reflect those measured prospectively(5, 20).
In our cohort, almost one third of patients with type 1 diabetes fulfilled the criteria for IAH. 
This high prevalence is comparable with studies done in other parts of the world dating back 
to the 1990s, when intensive insulin treatment and frequent glucose (self-) measurements 
were not standard management. This observation is supportive for a genetic influence on 
the risk for IAH.  In conclusion, homozygosity Gly16 (GG) of the ADRB2 contributed modestly 
to the risk of IAH, especially when combined with Gln27Glu (CG) heterozygosity. Our analysis 
revealed no other candidate genes related to IAH or severe hypoglycaemia. Future integration 
of clinical and genetic determinants may help to set individual treatment targets for glucose 
control to maximize gain and minimize harm for each individual with type 1 diabetes.  
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Abstract:
Introduction
Severe hypoglycaemia is reportedly associated with excess mortality and morbidity in type 
2 diabetes. We studied whether severe hypoglycaemia (SH) and impaired hypoglycaemia 
awareness, as principal predictor of SH, are associated with all-cause mortality in type 1 
diabetes. 
Methods
Mortality was recorded in two cohorts from Denmark (n=269, follow-up 12 years) and the 
Netherlands (n=482, follow-up 6.5 years). In both cohorts awareness class was characterized 
and numbers of episodes with severe hypoglycaemia either during lifetime (Danish) or during 
the preceding year (Dutch) were recorded. In addition, episodes with severe hypoglycaemia 
were prospectively recorded every month for one year in the Danish cohort. Follow-up data 
regarding mortality were obtained through medical reports and registries (Danish cohort). 
Results 
All-cause mortality was 15% (N=39) in the Danish and 4% (N=20) in the Dutch cohort. In either 
cohort, neither severe hypoglycaemia nor hypoglycaemia awareness status were associated 
with increased mortality in age-truncated Cox proportional hazards regression models. 
Variables associated with increased risk of all-cause mortality in both cohorts were evidence 
of macrovascular disease and reduced kidney function. 
Conclusions
Severe hypoglycaemia and hypoglycaemia unawareness are not associated with increased 
risk of all-cause or cardiovascular mortality in patients with type 1 diabetes. 
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Introduction 
Hypoglycaemia is the most frequent acute complication of insulin treatment. It has a 
negative impact on perceived quality of life and constitutes the principal limiting factor 
for achieving and maintaining optimal glycaemic control in patients with type 1 diabetes 
(1). Patients and health care professionals are particularly fearful of severe hypoglycaemia, 
which requires help from another person to restore blood glucose levels, thus creating a risk 
for physical damage (e.g. in traffic) (2, 3). It is estimated that patients with type 1 diabetes 
experience on average at least one severe hypoglycaemic episode every year (4), but the 
distribution is highly skewed (5). Patients suffering from impaired hypoglycaemic awareness 
or hypoglycaemia unawareness, which affects up to one third of patients with type 1 diabetes, 
are at highest risk of such events (6-8).  
The potential contribution of severe hypoglycaemia to mortality in patients with diabetes has 
received much attention since excess mortality during intensive glycaemic treatment of type 
2 diabetes was reported in the ACCORD study, particularly in those patients with a history 
of cardiovascular disease (9). In this study as well as in the ADVANCE study, examining the 
effect of strict glycaemic control in type 2 diabetes, occurrence of severe hypoglycaemia was 
associated with excess mortality from both cardiovascular and non-cardiovascular causes 
(10, 11). It is presently discussed whether severe hypoglycaemia is a marker for an increased 
risk of adverse clinical outcomes associated with co-morbidities rather than a direct cause 
(11, 12). 
Patients with type 1 diabetes have a much higher rate of severe hypoglycaemia, albeit less 
cardiovascular comorbidity compared to patients with type 2 diabetes (13-16). Thus, studying 
the potential association between severe hypoglycaemia and mortality is particularly 
relevant in the type 1 diabetic population since it might yield clearer results regarding a causal 
relationship. No studies of an association between occurrence of severe hypoglycaemia or 
impaired hypoglycaemic awareness and mortality have been published for type 1 diabetes. 
We therefore studied the relationship between severe hypoglycaemia and long-term all-
cause mortality and cardiovascular mortality in two cohorts of patients with type 1 diabetes. 
Since impaired hypoglycaemic awareness is the major known risk marker for chronic 
recurrent severe hypoglycaemia (5), an analysis of the association between hypoglycaemia 
awareness status and mortality is also included.  
Materials and methods
Data were derived from prospective observational studies in two independent outpatient 
cohorts from Denmark and the Netherlands. The studies were approved by local ethics 
committees in Denmark and the Netherlands. All participants signed a written informed 
consent form before entering the studies. 
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The Danish Cohort
The Danish Cohort included 269 patients with type 1 diabetes recruited from the diabetic 
outpatient clinic at Nordsjællands Hospital Hillerød in 1999-2001 (Table 1). Inclusion 
criteria were age >18 years and diabetes > 2 years. Patients who were pregnant, were on 
haemodialysis, or had severe concomitant disease were excluded from participation. Type 1 
diabetes was defined as need for insulin therapy from the time of diagnosis and unstimulated 
C-peptide concentrations < 300 pmol/l or stimulated (venous blood glucose concentration 
>12 mmol/l) C-peptide concentrations < 600 pmol/l. 
At baseline, the patients filled in a questionnaire including questions about hypoglycaemic 
exposure. The following data were collected: number of episodes of severe hypoglycaemia 
during lifetime and number of episodes of severe hypoglycaemia during the last 2 years before 
entering the study. Severe hypoglycaemia was defined as an episode at which third party 
assistance was needed in order to restore blood glucose levels. Awareness of hypoglycaemia 
was scored by the patients by the Pedersen-Bjergaard method which characterizes patients 
as either aware, impaired aware or unaware of hypoglycaemia (17, 18). 
The cohort was subsequently followed for 1 year. During this period any episode with severe 
hypoglycaemia was recorded and validated by a telephone interview within 24 hours (19). 
Furthermore, data on severe hypoglycaemia requiring medical assistance at a hospital 
during the entire follow-up period was retrieved from the National Patient Register. The 12-
year follow-up data on mortality and morbidity were assessed through searches in patients’ 
medical records as well as in Danish registries including the Central Office of Civil registration, 
the Danish Cause of Death Register and the National Patient Register. Four patients lost to 
follow-up are included in the survival analyses until their last contact but they were not 
included in the registration of the number of episodes with severe hypoglycaemia requiring 
hospitalization within the last 11 years of the study and therefore not included in this part of 
the analyses. 
The Dutch Cohort 
The Dutch cohort included 482 patients with type 1 diabetes recruited from the outpatient 
diabetes clinic of the Radboud University Medical Center in 2006-2008 (table 1), excluding 
four patients without any contact after the baseline visit. All patients were classified as 
having type 1 diabetes according to the need for immediate insulin therapy and related 
clinical information. At baseline, clinical data were collected from the patients’ medical 
records. Hypoglycaemia awareness status was classified according to a Dutch modification 
of the Clarke questionnaire, consisting of 5 questions, where patients with a score <3 were 
considered to have normal awareness and those with a score of 3 or above were considered to 
have impaired awareness (20, 21). Information regarding episodes with severe hypoglycaemia 
in the preceding year was also obtained. The definition of severe hypoglycaemia matched 
the Danish definition. In the Dutch cohort, there was a mean follow-up time of 6.5 years. 
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Information regarding mortality was assessed through the patients´ medical reports from 
the hospital and the family physician. 
Statistics 
Survival analyses were performed based upon age-truncated univariate and multivariate 
Cox proportional hazards regression models (22). Analyses were carried out for each of the 
hypoglycaemic variables. Data were processed using the SPSS software package (Version 
20.0, IBM Corporation, New York, USA) and the SAS software package (version 9.3, SAS 
Institute Inc, NC, USA). The level of statistical significance was chosen as <0.05 (two-sided). 
Results 
The Danish cohort 
A total of 39 patients died during 12 years of follow-up (15 %). The causes of death are 
listed in Table 2. Cardiovascular disease was the cause of death in 13 cases. In one case, 
hypoglycaemia was indicated as primary cause of death with alcohol listed as a contributing 
factor. 
A univariate, age-truncated, Cox proportional hazards regression model was applied to 
each of the hypoglycaemic variables as well as awareness status. None of the variables were 
significantly associated with increased risk of all-cause mortality or cardiovascular mortality 
(Table 3). 
Baseline variables positively associated with increased risk of all-cause mortality in a 
univariate, age-truncated, Cox proportional hazards regression model were male gender, 
duration of diabetes, presence of any macrovascular complications, presence of diabetic 
nephropathy, presence of hypertension and HbA1c at baseline (Table 4). 
Multivariate, age-truncated, Cox proportional hazards regression models were performed for 
each of the hypoglycaemic variables as well as awareness status and none of the variables 
were associated with increased all-cause mortality or cardiovascular mortality. 
The Dutch cohort 
A total of 20 patients died during 6.5 years of follow-up (4 %). The causes of death are listed 
in Table 2. Cardiovascular disease was the cause of death in 9 cases. Hypoglycaemia was not 
listed as primary cause of death in any case. A univariate, age-truncated, Cox proportional 
hazards regression model was applied to each of the hypoglycaemic variables as well as 
awareness status (Table 3). None of the variables were associated with an increased risk of 
all-cause mortality or cardiovascular death. There were however trends towards associations 
between increased risk of cardiovascular death and occurrence of severe hypoglycaemia 
in the last year before baseline (HR=3.3, p=0.08) and impaired hypoglycaemic awareness 
(HR=3.6, p=0.07). 
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Baseline variables associated with increased risk of all-cause mortality in the Dutch cohort were 
presence of macrovascular complications, presence of retinopathy, and estimated GFR of ≤30 
ml/min/1.73 m2, using the Modification of Diet in Renal Disease (MDRD) formula (Table 4). 
Multivariate, age-truncated, Cox proportional hazards regression models were performed 
for the hypoglycaemic variable and awareness status and none of them associated 
with increased all-cause mortality. A multivariate analysis was not performed to assess 
cardiovascular mortality due to the few cases of cardiovascular death. 
Table 1: Baseline characteristics of the two cohorts
Total 
population
Patients 
alive
Patients 
deceased
Danish cohort (N=269) 
Sex (% males) 60 60 74
Age (years) (mean ± SD) 45 ± 13 42  ± 11 62  ± 11
Duration of diabetes (years) (mean ± SD) 20 ± 12 19 ± 10 29 ± 15
HbA1c (%) (mean ± SD) 8.6 ± 1.2 8.6 ±1.2 8.8 ± 1.1
On insulin analogue treatment (%) 4.9 4.4 7
Presence of 
	 hypertension, patient reported (%)
	 any macrovascular complication (%)
	 diabetic nephropathy (%)
	 microalbuminuria (%)
	 neuropathy (%)
18
8
10
17
34
13
4
7
14
26
51
26
29
32
80
Dutch cohort (N=482)
Sex (% males) 46 47 45
Age (years) (mean ± SD) 46 ± 14 45  ± 13 59 ± 16
Duration of diabetes (years) (mean ± SD) 26 ± 13 25 ± 12 39 ± 18
HbA1c (%) (mean ± SD) 7.9 ± 1.2 7.9 ± 1.2 8.1 ± 1.4
On insulin analogue treatment (%) 93 93 80
Presence of 
	 hypertension, BP>130/80 (%)
	 any macrovascular complication (%)
	 diabetic nephropathy (%)
	 microalbuminuria (%)
	 neuropathy (%)
62
14
10
11
37
61
12
16
11
36
80
65
29
20
78
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Table 2: Causes of death
Danish cohort
N=39 (%)
Dutch cohort
N=20 (%)
Cardiovascular disease 13 (33%) 9 (45%)
Non-Cardiovascular disease
	 Infection
	 Cancer
	 Trauma
	 Hypoglycaemia 
	 Other
22 (57%)
8
5
2
1
6
9 (45 %)
1
0
1
0
7
Unknown
Time lag*
4 (10%)
3
2 (10%)
-
* Cases where the patient was deceased according to the Central Office of Civil registration but the cause of death 
was not yet registered in the Cause of Death Register due to a time lag.  
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Table 3: Results from the univariate, age-truncated, Cox proportional hazards regression model for each of the 
hypoglycaemic variables and either all-cause mortality or cardiovascular mortality in the Danish and Dutch cohort.
Hypoglycaemic Variable Distribution 
within the 
cohorts
All-cause 
mortality
Hazard Ratio 
(95% CI)
P Cardiovascular 
mortality
P
Danish cohort
SH (lifetime)
	 0 episodes (ref)
	 1 episode
	 2-5 episodes
	 >5 episodes
N=258
30 %
16%
23%
31 %
1
0.81 (0.20-3.3)
0.59 (0.12-3.0)
0.83 (0.24-2.8)
0.8
0.5
0.8
1
0.35 (0.04-2.9)
0.84 (0.21-3.4)
0.46 (0.11-1.9)
0.3
0.8
0.3
SH (2 years before baseline)
0 episodes (ref)
1 episode
2-5 episodes
>5 episodes
N=268
55 %
14 %
20 % 
11 %
1
0.42 (0.05-3.4)
0.52 (0.11-2.4)
0.64 (0.14-2.9)
0.4
0.4
0.6
1
0* 
0.42 (0.05-3.4)
1.17 (0.30-4.5)
0.99
0.4
0.8
SH (1-year prospective registration)
0 episodes (ref)
1 episode
>1 episodes
N=227
64 %
21 %
15 %
1
0.93 (0.29-3.0)
0.27 (0.04-2.1)
0.9
0.2
1
0.52 (0.10-2.6)
1.5 (0.37-5.8)
0.4
0.6
SH (requiring medical assistance during 
follow-up)
No (ref)
Yes 
N=265
69 %
15 %
1
0.94 (0.48-1.9) 0.9
1
1.1 (0.35-3.8) 0.9
Awareness status
Normal awareness (ref)
Impaired awareness
Unaware
44 %
44%
12 %
1
1.0 (0.49-2-09)
0.72 (0.29-1.81)
1.0
0.5
1
1.4 (0.43-4.6)
0.67 (0.13-3.5)
0.6
0.6
Dutch cohort
SH (1 year before baseline)
No (ref)
Yes
N=482
79 %
21 %
1
1.7 (0.64-4.4) 0.3
1
3.3 (0.88-12.2) 0.08
Awareness status
Normal awareness (ref)
Impaired awareness 
N=482
68 %
32 %
1
1.2 (0.48-2.9) 0.7
1
3.6 (0.90-14.5) 0.07
SH= Severe hypoglycaemia   *No CVD death in this group.
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Table 4: Baseline variables associated with increased risk of mortality in the two cohorts. 
Baseline variables associated with increased 
mortality
Danish cohort Dutch cohort
Hazard Ratio
(95% CI)
P Hazard Ratio
(95% CI)
P
Male gender 3.7 (1.5-9.0) 0.005 - -
Duration of diabetes (per year) 1.03 (1.0-1.1) 0.04 - -
Presence of any macrovascular complication 2.5 (1.1-5.8) 0.03 3.8 (1.4-9.8) 0.007
Presence of diabetic nephropathy (Danish cohort) or 
MDRD* <30 (Dutch cohort) 
4.3 (2.0-9.1) p<0.001 12.1 (2.6-56) 0.002
Presence of retinopathy 2.7 (1.2-6.3) 0.02 4.0 (1.2-13.8) 0.03
Presence of hypertension 2.4 (1.2-4.9) 0.01 - -
HbA1c at baseline (per % increase) 1.4 (1.0-1.8) 0.03 - -
Smoking 1.6 (0.8-3.1) 0.15 - -
*) Estimated GFR using the Modification of Diet in Renal Disease (MDRD) formula
Discussion 
This study shows that in two unselected cohorts of patients with type 1 diabetes neither 
severe hypoglycaemia nor impaired hypoglycaemic awareness is associated with increased 
risk of all-cause mortality or cardiovascular mortality during a follow-up of 12 and 6.5 
years, respectively. The annual proportion of patients reporting an episode with severe 
hypoglycaemia was 36% in prospective analysis (Danish cohort) and 21% in retrospective 
analysis (Dutch cohort) while 56 % (Danish) and 32 % (Dutch) of patients could be classified 
as having impaired hypoglycaemic awareness although the method for classification differed 
slightly between the two groups. These proportions are in line with previous estimates in 
patients with type 1 diabetes (4-8, 23). 
Our findings contrast with findings in patients with type 2 diabetes, where occurrence of only 
one episode of severe hypoglycaemia has been found to predict death and other important 
clinical outcomes in the following years, raising the question as to whether hypoglycaemia 
contributes to an increased risk of such events (24). This apparent discrepancy between type 
1 and type 2 diabetes may be explained first by differences in the prevalence of cardiovascular 
comorbidity, being low in the type 1 diabetic populations studied and higher in those with 
type 2 diabetes (16). Patients with type 2 diabetes may be more vulnerable to hypoglycaemia-
induced injury when there is evidence of atherosclerosis. Indeed, hypoglycaemia can reduce 
myocardial blood flow reserves and provoke symptoms and signs of myocardial ischemia 
in diabetic patients with coronary heart disease (25-27). Secondly, frequent hypoglycaemic 
events, which are typical for patients with type 1 diabetes, have been shown to provide some 
protection against hypoglycaemia-induced mortality in rodents (28). In support, a recent 
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analysis from the ACCORD study suggested that mortality was inversely related to the number 
of self-reported hypoglycaemia and the degree of hypoglycaemic awareness in intensively 
treated type 2 diabetes (29). 
Our results extend those from an analysis from the EURODIAB study reporting no association 
between occurrence of severe hypoglycaemic episodes and cardiovascular events in 
patients with type 1 diabetes without cardiovascular disease at baseline, although mortality 
was not analysed (30). In contrast, McCoy et al. (31) reported that severe hypoglycaemia was 
associated with a 3.4-fold risk of mortality in a mixed cohort of 1,013 patients with type 1 or 
type 2 diabetes. However, although the authors stated this association to be independent 
from diabetes type, only about one fifth of the patients in the cohort had type 1 diabetes. 
Also, mortality rate in these patients was lower than in the patients with type 2 diabetes, so 
that only 21 out of the total of 140 deaths (15 %) applied to patients with type 1 diabetes. 
The mortality rate was higher in the Danish cohort compared to the Dutch, but the follow-up 
time was also longer. When only the first six years of observation were analysed, the rates 
were very similar at 4.5% and 4.1% in the Danish and Dutch cohorts, respectively. Several 
factors may contribute apart from length of observation time. In the Danish cohort, glycaemic 
control was poorer at baseline and average age was approximately 4 years higher at the end 
of follow-up compared with the Dutch cohort. In addition, the proportion of men was higher 
in the Danish cohort. In the Dutch cohort, more patients received treatment with insulin 
analogues at baseline. This can be seen as a sign of the shift in treatment paradigms that 
occurred largely after establishing the initiation of the Danish cohort (32). Both male sex and 
elevated HbA1c were associated with increased risk of mortality in the Danish cohort. In spite 
of the higher mortality in the Danish cohort, hypertension was more prevalent in the Dutch 
cohort. However, this discrepancy might be due the fact that the prevalence was based on 
patient reports in the Danish cohort and on blood pressure measurements at the hospital in 
the Dutch cohort. 
Hypoglycaemia in type 1 diabetes is occasionally fatal, for instance as a consequence 
of cardiac arrhythmias (i.e. bradycardia or ventricular tachycardia), severe brain energy 
depletion or its occurrence under unfortunate circumstances leading to accidents (33-36). 
It can however be difficult to establish it as the cause of death (37) and hypoglycaemia may 
therefore be ignored as a potential cause of death. It is estimated that hypoglycaemia is the 
cause of death in approximately 2 to 6% of all deaths in the type 1 diabetic population, yet 
this estimation stems from the early 1990s (38). Results from the two cohorts suggest that 
hypoglycaemia as a cause of death is rare and episodes with severe hypoglycaemia are not 
associated with increased risk of mortality. However, both cohorts were young and relatively 
healthy, so that the number of deaths was limited. Further studies are warranted to assess 
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whether severe hypoglycaemia might be associated with adverse outcomes in an older 
cohort with more concomitant disease. 
The strengths of this study are that results are based on prospective observations in 
cohorts from two different European countries. Furthermore, awareness classification has 
been based on two different validated questionnaires. There is no international consensus 
regarding classification of awareness status. In this study both a simple and a more elaborate 
method was used and the results are the same. Severe hypoglycaemia was defined similarly 
in the two cohorts and episodes were both recorded retrospective and prospectively. Finally, 
in both cohorts the expected conventional risk factors for mortality could be reproduced 
statistically significant. 
The limitations to this study are the following. First, we were unable to combine the two 
cohorts, because there was a difference in the periods of time used to register severe 
hypoglycaemia. We do not think that this had any influence on the results since we 
investigated both episodes during lifetime, 2 years before baseline, 1 year before baseline 
and 1 year after baseline, neither of which was associated with increased mortality. Also, 
episodes with severe hypoglycaemia were not recorded in the complete follow-up period 
in either cohort. Ideally this would have to be done in a long-term prospective study to rule 
out any uncertainties. Finally, the number of patients dying from cardiovascular disease were 
few, so that the play of chance cannot be excluded when interpreting its association with 
severe hypoglycaemia and impaired hypoglycaemic awareness. 
Conclusion
Severe hypoglycaemia or impaired hypoglycaemic awareness as the strongest risk factor for 
severe hypoglycaemia are not associated with an increased mortality risk in patients with 
type 1 diabetes. This is an important finding, given the high frequency of and general anxiety 
about especially severe hypoglycaemia in the type 1 diabetic population and its limiting role 
in achieving optimal glucose control. 
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Summary 
It was first noted in the 1940s that many patients with type 1 diabetes have lost autonomic 
symptoms as early warning signs of hypoglycaemia, and proceed directly to neuroglycopenic 
manifestations (1). We now call this phenomenon impaired awareness of hypoglycaemia 
(IAH) and know that it results from a process of habituation to recurrent hypoglycaemia 
(Chapter 1). Long diabetes duration, low HbA1c and unmeasurable C-peptide levels, all of 
which increase the risk of hypoglycaemia, are therefore also risk factors for IAH. As outlined in 
Chapter 1, classical risk factors cannot explain the total burden of IAH among the population 
with type 1 diabetes. In this thesis, we estimated the prevalence of IAH over time, investigated 
the potential impact of genetic predisposition for its occurrence and analysed whether IAH 
affects mortality. 
For most patients with type 1 diabetes, hypoglycaemia remains the most important limitation 
in the pursuit of optimal glycaemic control and many patients are prone to counter regulatory 
defects including IAH (2). In the past 30 years, the prevalence of IAH was estimated in various 
type 1 diabetes cohorts around the world at 20-30% (3-6). Since then, basal-bolus insulin 
regimens with insulin analogues, continuous subcutaneous insulin infusion (CSII), frequent 
glucose monitoring and structured educational programs have become standard therapy for 
patients with type 1 diabetes (7). Since all of these developments are associated with lower 
risks of hypoglycaemia, we were interested in the current prevalence of IAH and also whether 
it had changed over time (Chapter 2). Our first analysis among 485 consecutive patients with 
type 1 diabetes disclosed a prevalence of IAH of 32.5%, certainly not lower than previous 
estimates performed elsewhere. Moreover, although a low HbA1c-level was a strong risk 
factor for IAH, high HbA1c levels certainly did not protect against its occurrence. Other clinical 
factors associated with IAH included male gender, age, duration of diabetes and impaired 
renal function (GFR<30ml/min.). Remarkably, when we repeated the questionnaire several 
years later, the vast majority of patients with IAH still had IAH and the overall prevalence of 
IAH had not changed. 
The more or less stable prevalence of IAH over time and across various type 1 diabetes cohorts 
suggests the contribution of a genetic propensity for the development of IAH. In Chapter 
3, we therefore studied the role of polymorphisms in the beta2-adrenergic receptor in the 
occurrence of IAH in a population of type 1 diabetes. Since homozygosity Gly16 of the beta2-
adrenergic receptor makes this receptor particularly prone to a process of desensitization 
upon repeated stimulation (8, 9), such as may occur during hypoglycaemia, we posited that 
patients with type 1 diabetes with this SNP would be at high risk of developing IAH. This 
hypothesis was first tested in a relatively small cohort of unselected patients with type 1 
diabetes, described in chapter 3. In this study, we found that patients homozygous gly16 for 
the beta2-adrenergic receptor were at an approximately threefold greater risk of having been 
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diagnosed with IAH than patients without this polymorphism. A limitation of this study was 
that its small sample size precluded an analysis of linkage disequilibrium, which is known to 
exist between two frequently occurring SNPs in the beta2-adrenergic receptor. 
To examine the role of beta2-adrenergic receptor in the development of IAH in more 
depth, we investigated the effect of antecedent hypoglycaemia as a model of IAH on next-
day beta2-adrenergic sensitivity in healthy volunteers. Beta2-adrenergic sensitivity was 
assessed by measuring the forearm blood flow response to intra-arterial infusion with the 
beta2-adrenergic receptor agonist, salbutamol, and we enrolled subjects who were either 
homozygous Arg16 or homozygous Gly16 for the beta2-adrenergic receptor (Chapter 4). 
Somewhat surprisingly, antecedent hypoglycaemia increased rather than reduced next-
day beta2-adrenergic sensitivity in the whole group. This effect appeared to be driven solely 
by the homozygous Arg16 subjects, who showed a significant increase in beta2-adrenergic 
sensitivity, whereas this effect was blunted in the gly16 homozygous subjects. These data 
argue against a direct role for reduced beta2-adrenergic sensitivity in the pathogenesis 
of IAH. Instead, the enhanced beta2-adrenergic sensitivity after hypoglycaemia in Arg16 
homozygous subjects potentially serves as a protective mechanism to retain or even improve 
the detection of future hypoglycaemic events. Such a protective response appears to be 
absent in subjects homozygous for gly16, possibly explaining their propensity for developing 
IAH. It could also be speculated that exposure to many more hypoglycaemic events, as is 
the case in patients with type 1 diabetes and IAH (10-17), are required to eventually reduce 
sensitivity of the beta2-adrenergic receptor. 
In Chapter 5 we compared hemodynamic responses to systemic adrenaline infusion 
between men and women. This study revealed intriguing differences between de sexes, 
with men showing predominately beta2- and possibly beta1-adrenergic effects and women 
showing mainly alpha-adrenergic effects following adrenaline infusion that resulted in 
similar plasma levels as obtained during hypoglycaemia. Males have been reported to be 
at slightly higher risk of developing IAH than females (18-21). Since the adrenergic part of 
autonomic symptom responses to hypoglycaemia is mediated through beta-adrenergic 
receptor stimulation, this greater susceptibility in men for IAH may be explained partly by 
such differences in the sensitivity to adrenaline. 
In an effort to confirm our results on the relation between beta2-adrenergic receptor 
polymorphisms and IAH and to put these into context of previously reported genetic factors 
associated with either the occurrence of severe hypoglycaemia or hypoglycaemia (22, 23), we 
performed a larger cohort study. Patients from our outpatient department were asked about 
their awareness status using the same validated questionnaire and blood was drawn for 
DNA analysis. In this study, discussed in Chapter 6, we were able to reproduce our previous 
results by showing a greater prevalence of IAH in subjects homozygous gly16 than in subjects 
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without this SNP. Haplotype analysis, performed because of linkage disequilibrium between 
the SNPs at codons 16 and 27, disclosed that Gly16Gly patients who were heterozygous 
Gln27Glu were at the highest risk of IAH. Neither SNP of the beta2-adrenergic receptor, or one 
of the other genes studied were a risk factor for severe hypoglycaemia and none of the other 
genetic factors was associated with IAH. The magnitude of the association was comparable 
to that of clinical risk factors for IAH, including HbA1c, age, duration of diabetes and gender, 
correction for which only slightly modified the relationship between beta2-adrenergic 
receptor polymorphisms and IAH. 
There is now substantial evidence that links severe hypoglycaemia to mortality, both in 
people with type 1 or type 2 diabetes and in patients treated with insulin on the ICU. Given 
that IAH is the most important risk factor for severe hypoglycaemia in people with type 1 
diabetes, we aimed to explore the relationship between IAH and mortality. For this purpose, 
we collaborated with a research team from Denmark to combine their cohort of 269 patients 
(follow-up, 12 years) with ours of 482 patients (follow-up, 6.5 years). In neither cohort, IAH was 
associated with increased (or decreased) mortality (Chapter 7). In the Dutch cohort, there 
was a borderline significant association between IAH and cardiovascular mortality, which 
should be further explored. One possibility is that this was the result of fatal arrhythmia, 
since (nocturnal) hypoglycaemia has been shown to cause QTc-lengthening (24, 25), a well-
known predictor of ventricular tachycardia syndromes. However, the association between 
IAH and cardiovascular death in our cohort was based on very low numbers (n=9) and was 
not mirrored in the Danish cohort, so that the play of chance cannot be excluded.
General discussion and future perspectives
Based on the research results presented in this thesis, several conclusions can be drawn. First 
of all, our results clearly show that IAH is still highly prevalent among patients with type 1 
diabetes, despite the introduction of new insulin analogues and insulin delivering devices, all 
aimed at reducing the burden of hypoglycaemia. We also show that IAH is quite stable over 
time: three out of four patients affected at the first assessment retained IAH when questioned 
several years later. 
Because classical clinical risk factors, including low HbA1c, loss of residual beta-cell function 
and duration of diabetes, do not explain the full extent of IAH, we hypothesized involvement 
of genetic predisposition. Indeed, genetic variation in the beta2-aderenergic receptor 
appears to play a role in the pathogenesis of IAH, with patients with homozygosity for Gly16 
being slightly more prone for developing IAH, especially when combined with the Glu27Gln 
genotype. However, the underlying mechanism explaining this genetic predisposition 
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remains to be revealed, especially since hypoglycaemia did not reduce beta2-adrenergic 
sensitivity.
Other researchers earlier reported other polymorphisms, including that of the ACE gene, 
to predispose for increased risk of severe hypoglycaemia. None of these genetic factors, 
however, appeared to be related to IAH or to the occurrence of severe hypoglycaemia in our 
cohort. Genetic research in much larger cohorts of patients with type 1 diabetes is needed to 
examine the potential role of these genotypes in the development of IAH and may uncover 
new candidate genes related to IAH. Since IAH also affects up to 10% of patients with type 2 
diabetes on insulin, such genetic studies are also needed in the type 2 diabetes population, 
especially since the number of patients at risk of hypoglycaemia increases at alarming speed.
Finally, we are the first to investigate the consequences of IAH on long-term clinical outcomes. 
We did not identify a link between IAH (or SH) and increased (cardiovascular) mortality. 
This is important and reassuring news for patients with type 1 diabetes, their relatives and 
health-care providers, but certainly requires confirmation in larger cohorts. Our studies were 
performed before widespread use of glucose monitoring devices or flash glucose meters. The 
evidence that severe hypoglycaemic events can be avoided with these devices is now slowly 
emerging, but there is little evidence that these devices are able to reverse IAH. Whether 
genetics are involved in this apparent discrepancy should be the focus of further research.
Case vignette (continued)
The woman in the case vignette in Chapter 1 had asked her health care provider several 
questions about hypoglycaemia and the altered perception of these events. She is 
particularly interested in why she no longer feels hypoglycaemic events like she used to do 
and whether hypoglycaemia and her reduced ability to perceive hypoglycaemic symptoms 
are harmful. We can tell her that she clearly has IAH, which has probably contributed to the 
severe hypoglycaemic event that she recently encountered. Risk factors for IAH for her include 
her low HbA1c – reflecting tight glucose control – and long duration of diabetes, possibly 
indicating loss of residual beta-cell function. It is possible that genetic factors also play a 
role, but we cannot recommend genetic testing on the basis of this thesis. We can reassure 
her that there is no indication that IAH increases mortality. However, precautionary action is 
required to avert the risk of severe hypoglycaemia. Therapies targeting the beta2-adrenergic 
receptor will probably not help her regain awareness for hypoglycaemia. 
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Diabetes mellitus komt steeds vaker voor. In Nederland treft diabetes ruim 1 miljoen 
mensen. Er zijn grofweg twee vormen. De overgrote meerderheid heeft type 2 diabetes. 
Type 1 diabetes, waar ik het in dit proefschrift over heb, betreft 10% van het totale aantal 
patiënten met diabetes. Diabetes mellitus type 1 is een ziekte die veelal op jonge leeftijd 
optreedt en het gevolg is van het ten gronde gaan van cellen in de alvleesklier die insuline 
produceren. Insuline verlaagt de glucosespiegel in het bloed en is een onmisbaar hormoon 
voor de glucoseregulatie. Voor de ontwikkeling van insuline als geneesmiddel bijna 100 
jaar geleden, leidde diabetes mellitus type 1 onherroepelijk in korte tijd tot de dood. Nu 
we in staat zijn insuline als geneesmiddel toe te dienen, is direct overlijden als gevolg van 
een insulinetekort zeldzaam. Wel zijn patiënten met type 1 diabetes levenslang afhankelijk 
van insulinetoediening door middel van subcutane injecties. Daarbij wordt gestreefd naar 
een zo normaal mogelijke glucosespiegel, omdat een chronisch verhoogde glucosespiegel 
(hyperglykemie) leidt tot ernstige complicaties, zoals blindheid, nierschade, voetwonden  die 
kunnen leiden tot een amputatie, beschadiging  van zenuwen en hart- en vaatziekten. 
Zelfmanagement is de hoeksteen van de behandeling van type 1 diabetes. Dit betekent onder 
meer dagelijkse controle van de glucosespiegel en rekening houden met dieet, lichamelijke 
activiteit en gemoedstoestand. De afgelopen decennia zijn de verschillende beschikbare 
insulinepreparaten steeds verder verfijnd en is ook de technologie voor het toedienen van 
de insuline sterk verbeterd. Desondanks blijft de behandeling met insuline verre van ideaal 
en lukt het ondanks de huidige technologie niet om de werking van de alvleesklier volledig 
na te bootsen. Als er (relatief) te weinig insuline wordt gespoten blijft de glucose te hoog, bij 
te veel spuiten daalt de glucose te sterk. Een te lage glucosewaarde wordt hypoglykemie of 
hypo genoemd. 
Patiënten met type 1 diabetes hebben gemiddeld twee maal per week een hypo. Het 
voortdurend aanwezige risico op een hypoglykemie maakt dat het voor een patiënt 
voorzichtig opereren is en er niet te rigoureus insuline kan worden toegediend. Normaal 
stimuleert een hypo het vrijkomen van stresshormonen (vooral adrenaline)en  veroorzaakt 
daarmee herkenbare verschijnselen. Bij een deel van de patiënten met type 1 diabetes treden 
die symptomen niet of in verminderde mate op. Dit verminderde gevoel voor hypo’s wordt 
‘impaired awareness of hypoglycaemia’ (IAH) genoemd. IAH is het gevolg van gewenning aan 
herhaalde hypo’s. Als hypo’s geheel worden vermeden komen de normale verschijnselen 
weer terug.  Patiënten met IAH hebben een 6 keer grotere kans op het krijgen van een ernstige 
hypo waarbij ze zelf niet meer in staat zijn de glucosespiegel in het bloed te corrigeren en 
afhankelijk zijn van hulp van anderen. Daardoor kunnen ze in gevaarlijke situaties terecht 
komen (bijv. in het verkeer) of zelfs overlijden. 
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IAH komt bij 20-30% van de patiënten met type 1 diabetes voor. Lange diabetesduur en 
een scherpe instelling van de diabetes verhogen het risico. Daarbuiten blijft het een raadsel 
waarom sommige patiënten hypo’s wel blijven voelen en anderen niet. Mogelijk spelen 
genetische factoren een rol. Doel van dit proefschrift is dan ook om de rol van deze factoren 
bij het ontstaan van IAH verder te onderzoeken. 
Voor het eerste onderzoek, beschreven in hoofdstuk 2, onderzochten we een groep van 
bijna 500 patiënten met type 1 diabetes van de diabetespolikliniek van het Radboudumc. 
In deze groep bleek IAH bij 1 op de 3 patiënten voor te komen. Zoals verwacht vonden we 
dat IAH vaker voorkwam bij patiënten met een goede diabetesinstelling (lager HbA1c). Een 
slechte(re) instelling bood geen bescherming; IAH kwam ook voor bij 20% van de patiënten 
met een heel hoog HbA1c. Toen we het onderzoek na vier jaar herhaalden zagen we dat 
bij gemiddeld 3 van de 4 patiënten  het al dan niet aanvoelen van hypo’s stabiel bleef.  Dit 
versterkte de gedachte dat er genetische factoren zouden kunnen bestaan die het risico op 
IAH beïnvloeden. 
In het onderzoek naar een genetische factor heb ik me als eerste gericht op de beta2-
receptor. Dit is een eiwit in de celmembraan waaraan stresshormonen zoals adrenaline en 
noradrenaline kunnen binden. Deze binding zet processen in gang die ook belangrijk zijn voor 
een goede reactie op een hypo. Verminderde gevoeligheid van deze receptor is beschreven. 
Daarom onderzochten we of deze verminderde gevoeligheid vaker voorkomt bij patiënten 
met IAH. In hoofdstuk 3 beschrijven we de uitkomsten van een pilotstudie waarbij we in 
een kleine groep van 85 patiënten met type 1 diabetes hebben gekeken of er een verband 
bestaat tussen het voorkomen van IAH en een aanpassing in het gen dat codeert voor deze 
beta2-receptor (een zogenaamd single nucleotide polymorphism, SNP). Deze studie toonde 
aan dat patiënten met deze bepaalde variant van de receptor een ruim 3 maal zo hoog risico 
bleken te hebben op het krijgen van IAH. 
In hoofdstuk 4 beschrijven we een studie waarbij we hebben gekeken of we met een 
experiment konden bewijzen dat hypoglykemieën daadwerkelijk de gevoeligheid van 
deze beta2-receptor verminderen en dat dit afhankelijk is van een variant van dit eiwit.  We 
hebben dit onderzocht bij gezonde vrijwilligers die door middel van genetisch onderzoek 
werden geselecteerd op basis van de samenstelling van een bepaalde variant van de beta2-
receptor.  Twee groepen werden vergeleken, een met en een zonder die variant.  Op dag 
1 werd een proefpersoon twee maal blootgesteld aan een gecontroleerde  hypoglykemie. 
Op dag 2 dag werd bij dezelfde proefpersoon met twee andere technieken, door metingen 
aan de onderarm en de hartslag, de gevoeligheid voor zowel de beta2- als de beta1-receptor 
vastgesteld aan de hand van de reactie op salbutamol en isoprenaline. Tot onze verbazing 
bleek niet de groep met de variant een verlaagde gevoeligheid te hebben, maar had juist de 
andere groep een verhoogde gevoeligheid na blootstelling aan hypoglykemieën. Het zou dus 
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zo kunnen zijn dat een bepaalde variant van de beta2-receptor beschermend werkt in plaats 
van een tegenovergestelde variant die nadelig is. 
Omdat IAH mogelijk vaker voorkomt bij mannen dan bij vrouwen hebben we in  een 
experiment gekeken of  de reactie op een van de belangrijkste hormonen in reactie op een 
hypo, adrenaline, tussen mannen en vrouwen verschilde. Deze studie staat beschreven in 
hoofdstuk 5. Onze conclusie was inderdaad dat er subtiele verschillen zijn in gevoeligheid 
voor adrenaline waarbij stimulatie van beta-receptoren bij mannen meer op de voorgrond 
staat dan bij vrouwen. 
In hoofdstuk 6 beschrijven we de resultaten van een uitgebreid genetisch onderzoek 
in dezelfde groep van bijna 500 patiënten die we ook in hoofdstuk 2 hebben besproken. 
Daarmee probeerden we ten eerste de rol van de beta2-adrenerge receptor bij IAH te 
bevestigen (hoofdstuk 3). Daarnaast wilden we andere genetische varianten onderzoeken 
waarvan in andere publicaties was beschreven  dat zij mogelijk verband houden met het 
voorkomen van IAH of het optreden van ernstige hypo’s. Door het grotere aantal patiënten 
was het nu ook mogelijk te kijken naar combinaties van meerdere genetische varianten in de 
beta2-receptor. We vonden opnieuw een verband tussen SNP’s van de beta2-receptor en IAH. 
Wederom leek het zo te zijn dat patiënten met de variant op positie 16 van de beta2-receptor, 
die we eerder ook vonden in hoofdstuk 3, een verhoogd risico hadden op het krijgen van IAH. 
Dit verband werd sterker als er sprake was van een combinatie met een andere variant op 
positie 27. Wel was het verband minder groot dan we eerder hadden gevonden. Wij vonden 
geen verband met het voorkomen van ernstige hypo’s. Voor de genen die andere auteurs 
hadden gevonden werd in onze groep patiënten geen verband aangetoond, niet voor IAH en 
niet voor ernstige hypo’s. 
Bij patiënten met type 2 diabetes is een ernstige hypo een risicofactor voor overlijden, met 
name aan hart- en vaatziekten. In het laatste onderzoek (hoofdstuk 7) bestudeerden we 
daarom het mogelijke verband tussen IAH of ernstige hypo’s en het risico  op overlijden 
bij type 1 diabetes. Hiervoor hebben we gekeken naar de sterfte binnen onze eigen groep 
patiënten en deze gegevens hebben we gecombineerd met de gegevens van collega’s uit 
Denemarken. De geruststellende boodschap was dat, hoe vervelend een (ernstige) hypo en 
IAH ook is, er geen duidelijk verhoogd risico lijkt te zijn op vroegtijdig overlijden, ook niet als 
gevolg van hart- en vaatziekten.  
We hebben in dit proefschrift laten zien dat IAH nog steeds vaak voorkomt; in onze 
patiëntengroep bij ongeveer 1 op de 3 patiënten met type 1 diabetes, ondanks het feit dat 
de behandeling van type 1 diabetes de afgelopen decennia sterk is verbeterd. Ook is het 
voorkomen van IAH stabiel bij het merendeel van de patiënten. Verder hebben we laten 
zien dat er een verband bestaat tussen een bepaalde variant van de beta2-receptor en het 
voorkomen van IAH. Wat precies het mechanisme is achter dit verband is nog niet volledig 
134
opgehelderd. Voor andere genetische verschillen vonden wij geen aanwijzingen maar het 
is zeer wel mogelijk dat bij onderzoek in veel grotere groepen en met moderne genetische 
technieken, nieuwe verbanden kunnen worden aangetoond. Tot slot kunnen we patiënten 
geruststellen dat IAH of ernstige hypo’s niet geassocieerd lijkt te zijn met een verhoogde kans 
op sterfte. 
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Dit proefschrift markeert de afronding van een lang promotietraject waarmee ik in november 
2004 begon. Als je zolang over iets doet en het dan toch nog afrondt kan het niet anders dan 
dat je aan veel mensen dank verschuldigd bent. Toen ik in 2004, midden in mijn opleiding 
tot internist, begon aan dit traject kon ik niet vermoeden dat ik 14 jaar later nog steeds 
werkzaam zou zijn op de afdeling Farmacologie-Toxicologie en ik mij in de patiëntenzorg 
bijna helemaal zou wijden aan de zorg voor adolescenten en volwassenen met diabetes. 
Ik prijs mij gelukkig dat ik dit kan combineren met allerlei taken in het onderwijs waar ik 
ontzettend veel positieve energie van krijg. Iedereen die mij gesteund heeft op dit pad ben 
ik veel dank verschuldigd en dat heeft niet alleen betrekking op de totstandkoming van dit 
proefschrift. Sterker nog, de kansen die ik heb gehad in de patiëntenzorg en het onderwijs 
hebben eerder afgeleid van dit proefschrift maar hebben mij wel gemaakt tot de internist-
klinisch farmacoloog, diabetes behandelaar en docent die ik nu ben. Dat mijn proefschrift er 
zou komen stond vast, wanneer was steeds de vraag. Twijfel over de waarde van het eigen 
onderzoek is geen onderzoeker vreemd. Maar dat Brian Frier, winnaar van de Camillo Golgi 
prijs en een van de toonaangevende onderzoekers op het gebied van hypoglykemie, een 
aantal van de hoofdstukken uit dit proefschrift benoemde in zijn Award Lecture op de EASD 
in Lissabon afgelopen jaar, gaf mij extra energie het toch maar echt af te maken.  
Op de eerste plaats wil ik voor de totstandkoming van dit proefschrift iedereen bedanken 
die als patiënt/proefpersoon vragenlijsten heeft ingevuld, vrijwillig bloed heeft afgestaan 
voor DNA-onderzoek of zelfs heeft meegedaan aan de experimenten met langdurige hypo’s, 
infusen en arterielijnen.  Ik heb de eer sommige van deze patiënten nu zelf te mogen 
begeleiden bij de behandeling van hun diabetes. En sommige vrijwilligers van toen kom ik 
nu tegen als collega of zijn nog steeds familie. Zo ben ik blij dat ik na het experiment bij mijn 
schoonzus niet ben verbannen door mijn schoonfamilie. 
Dr. B.E. de Galan, beste Bastiaan. Ik kan me nog steeds herinneren dat ik ten tijde van 
mijn stage in het Jeroen Bosch ziekenhuis door jou werd gebeld met de vraag of ik geen 
promotieonderzoek bij je wilde doen. Ik was bezig met de consultenstage en was waarschijnlijk 
net aan het vloeken over chirurgen die niks begrijpen van diabetes. Ik had eigenlijk nog niet 
zo nagedacht over een promotietraject. Jij kende me nog uit de periode toen jij als ervaren 
collega assistent een beetje op mij, net begonnen jonkie, moest passen op de afdeling 
nierziekten. Je dacht waarschijnlijk toen nog dat ik wel een goede en snelle promovendus 
zou worden; ik was je eerste promovendus maar inmiddels ben ik ruim ingehaald door jouw 
latere promovendi. Ondanks jouw subtiele aansporingen heeft het te lang geduurd maar ben 
je me altijd blijven steunen. Frustrerend was soms dat ik na maanden zwoegen een concept 
artikel met een zucht van verlichting naar je opstuurde om het vervolgens een dag later rood 
gemarkeerd weer in mijn mailbox aan te treffen. Niks rustperiode, ik kon weer aan de bak. Aan 
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jouw snelheid heeft het dus niet gelegen. Wat heb ik je laten zakken als eerste promovendus, 
zeker nu de promotiedatum uiteindelijk in 2018 valt hetgeen eigenlijk 3 maanden te laat is 
voor je PI-aanvraag. Ik hoop dat de decaan flexibel is want met inmiddels een grote Europese 
subsidie op zak verdien je een PI-predicaat. Je hebt inmiddels je sporen nationaal maar ook 
internationaal op het gebied van hypo-onderzoek verdiend. Ik hoop nog jaren met je samen 
te werken als collega diabetes behandelaar. 
Prof. Dr. P.A.B.M. Smits, beste Paul. Wat was het een voorrecht om onder jouw vleugels 
te mogen starten met mijn promotietraject. Het warme bad van de afdeling Farmacologie-
Toxicologie, je nabijheid met de deur altijd open en de gezellige momenten, al of niet met 
een biertje, waren een enorme stimulans. Niet alleen om te promoveren maar ook om een 
academische carrière na te streven.  Jij had na een tijdje natuurlijk ook wel door dat mijn hart 
misschien meer bij patiëntenzorg, onderwijs of beleidszaken lag. Het is dan ook niet voor 
niks dat ik mij met jou als sparringpartner verdiepte in de diabetes/vasculaire patiëntenzorg 
en het onderwijs in de farmacologie. Jij nam mij in opleiding tot klinisch farmacoloog en 
jij stimuleerde mij om in de UMC-raad te gaan, medisch hoofd van het CRCN te worden en 
bij het IWKV aan de slag te gaan als auditor. Door jou kreeg ik een beetje een idee hoe het 
werkt in de top van een UMC. Beste Paul, we missen je nog steeds als aanjager van klinisch 
farmacologisch onderzoek, zeker op het gebied van de farmacotherapie van diabetes. 
Misschien kan ik daar in de toekomst nog een rol in spelen. Ik ben blij dat je ondanks je huidige 
positie als decaan en zelfs als tijdelijk voorzitter van de RvB van ons geliefde Radboudumc, 
betrokken bent gebleven bij mijn promotie. 
Prof. Dr. C.J.J. Tack, beste Cees. Aanvankelijk had jij eigenlijk niks van doen met mijn 
promotietraject. Maar de laatste jaren heb jij gelukkig de verantwoordelijkheid om dit 
proefschrift tot een afronding te brengen naar je toe getrokken. Dit heeft mij enorm 
geholpen. Jij hebt jezelf de afgelopen 15 jaar ontwikkeld als het Nijmeegse boegbeeld van 
de diabeteszorg en nadat je aanvankelijk misschien wel eens dacht ‘wat moet ik met die 
Bas’, werken we inmiddels veel samen in de patiëntenzorg en het (diabetes)onderwijs en 
voel ik me echt thuis binnen de diabetesgroep. Het was dan ook jouw idee om in het KDCN te 
stappen en ik hoop dat het ons lukt om samen met onze diabetes collega’s binnen en buiten 
het Radboudumc een krachtig netwerk neer te zetten voor alle patiënten, jong en oud, met 
type 1 diabetes in de regio Zuidoost-Nederland.
Prof. Dr. J.W.M. van der Meer en Dr. P.M. Netten, beste Jos en Paetrick. Ik ben met 
mijn proefschrift begonnen tijdens mijn opleiding tot internist in een zogenaamde AGIKO 
constructie. Hoewel de afronding van mijn opleiding  alweer enige tijd geleden is, hebben 
jullie mij als opleiders, samen met het hele opleidingsteam, gevormd tot de internist die ik nu 
ben. Ik ben ook erg vereerd Paetrick, dat jij participeert in de verdediging van mijn proefschrift 
vandaag. 
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Collega’s van de afdeling Farmacologie-Toxicologie. Het zijn teveel namen om te noemen 
en omdat het zo lang heeft geduurd zijn sommige collega’s en mede promovendi ook weer 
verdwenen. Ik bewaar dierbare herinneringen aan onze kamer met aanvankelijk Petra 
en Patrick, later met Ab en Joke en aan alle medewerkers die route 149 bewoonden en 
promovendi van het eerste uur. Mooie herinneringen aan de tijd dat we nog een ouderwetse 
kan filterkoffie maakten en thee in een pot die al lang geen nieuwe thee meer nodig had. Als 
staflid heb ik de laatste jaren, veel steun gehad van mijn klinische collega’s, mede stafleden 
en post-docs van de afdeling; waaronder mijn onderwijsmaatjes Kees, Rick en Suzanne 
die me soms uit de wind hielden omdat het misschien wel slim was als ik wat meer tijd aan 
mijn proefschrift zou besteden. Sowieso zou het onmogelijk zijn geweest alle taken uit te 
voeren zonder de ondersteuning van Wendy en Lilibeth. 
Prof. Dr. F.G.M. Russel, beste Frans. Jij gaf mij het vertrouwen als staflid van de afdeling en 
coachte mij met name in mijn onderwijsprofiel. Mede dankzij jou raakte ik betrokken bij de 
curriculumherziening en gaf jij mij de ruimte om mijn proefschrift af te ronden. 
Collega’s in de diabetes sectie, collega’s van de afdeling Interne Geneeskunde.  Ik 
voel me thuis in de diabetesgroep. Hoewel diabeteszorg geen formele opleiding kent ben 
ik er ingerold door spreekuren over te nemen van Paul en Bastiaan. Met begeleiding van 
Bernadette en Lammy maar zeker ook van de diabetesverpleegkundigen begon ik 
langzaam iets te begrijpen van pompen, pennen, meters en wizards. En ook mijn recente 
collega’s bij het KDCN leren mij weer nieuwe dingen en maken mij een completere diabetes 
behandelaar. Dat het allemaal draait om de patiënt, dat de arts vooral een gids, een coach is 
en begrippen als gedeelde besluitvorming  zit in het DNA van de diabetesgroep al lang voordat 
iedereen dit ging hypen. Daarnaast delen we als groep dezelfde passie voor onderwijs. Ik 
hoop nog lang met jullie te mogen samenwerken. 
Prof. Dr. J.W.A. Smit, beste Jan. We zien elkaar niet vaak en ik ben een beetje een vreemde 
eend in de interne bijt. Toch heb jij mij vanaf het begin gesteund. Ik vind bij jou altijd een 
luisterend oor en jij bent open en eerlijk. Mede dankzij jou voel ik me meer dan ooit thuis bij 
de interne geneeskunde en zal ik ook naar studenten en coassistenten met trots het vak van 
internist uitdragen. 
Tijdens mijn promotie en vooral ten tijde van de uitvoer van de verschillende studies heeft een 
aantal collega promovendi, inmiddels al lang werkzaam als specialist, mij geholpen. Ik denk 
daarbij aan Fleur Poelkens en Alexander Rennings die mij geholpen hebben bij de clamp 
studies. Bart Veldman hielp  met het opzetten van een database van patiënten waardoor we 
de pilotstudie konden uitvoeren. Hoewel ik daarna van voren af aan ben begonnen met het 
aanleggen van een nieuwe database borduurde dit voort op het werk van Bart. 
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Ook wil ik de collega’s van het CRCN bedanken die mij hebben geholpen bij de uitvoering van 
de studies. Zonder de hulp van Aarnout, Karin, Joyce en Anja was het nooit goed gekomen 
met de invasieve studies. 
Ik heb veel hulp gehad bij de opzet, uitvoering en interpretatie van de genetische onderzoeken 
van Barbara Franken en later vooral van Marieke Coenen. Ik begrijp nog steeds niet alles 
want het veld van de genetica heeft een dusdanig snelle ontwikkeling doorgemaakt dat ik 
die niet kon bijbenen. Ook ben ik de analisten van de afdeling klinische genetica dank 
verschuldigd voor het bepalen van alle samples.  En Marieke, fijn dat je vandaag tegenover 
mij staat, ik ga graag met je in discussie. 
Thanks to Prof. Dr. Pedersen-Bjergaard and Dr. Sejling, It was your initiative to merge 
our datasets. Ulrik, I don’t know if you still remember but we met in Friesland for the ADDDG 
meeting and sailed together on the lakes. I’m delighted that you join us today during my 
thesis defence. Anne-Sophie, you came to Amsterdam and together we made a draft for what 
turned out to be a paper and my 7th chapter. Besides that we talked about our kids. Thank 
you for taking the lead in this. 
Tessa, Esmee  en Lieke. Jullie hebben voor mij gespit in statussen, vragenlijsten ingevoerd, 
data geanalyseerd en zelfs een eerste aanzet gedaan voor een artikel. Voor Tessa was het 
nog even schrikken toen er op de EASD in Stockholm geen kamer beschikbaar leek te zijn in 
het hotel. Gelukkig werd dit snel opgelost en werd jouw poster, die de basis vormde van mijn 
huidige hoofdstuk 2, goed bezocht. 
Beste ‘jezus gast, waarom begrijp je dat zelf niet’  Maaike. Dat was een van jouw uitspraken 
toen je met Marjo aan het praten was over mijn proefschrift. Ik huurde je in om me te helpen 
met endnote gedoe en lay-out werk. Mede dankzij jou lukte het om de drempel te nemen om 
alles wat ik had liggen tot een echt manuscript te maken. 
Beste paranimfen, lieve Bernadette en Alexander. Alexander, ik was natuurlijk jouw paranimf. 
Ik heb me altijd aan jou gespiegeld omdat onze carrières veel overeenkomsten vertonen. Dat 
begon al bij onze gemeenschappelijk stage als assistent op de afdeling hematologie. Jij uit 
Leiden, ik uit Venlo. Je begon wat eerder dan ik aan je promotietraject en lang heb ik gedacht 
dat ik er niet zo lang over zou doen als jij. Tot jij daadwerkelijk promoveerde en ik een nieuwe 
deadline had. Die heb ik geloof ik niet gehaald. 
Bernadette, jij was mijn begeleider toen ik de poli van Bastiaan overnam tijdens zijn 
afwezigheid. Maar de afgelopen jaren zijn we vooral intensief gaan samenwerken in het 
onderwijs. We delen allebei de passie om van studenten echte dokters te maken en ik leer 
daarin veel van jou al zal ik je nooit inhalen in je precisie en stiptheid. In die zin ben jij veel 
meer een echte internist dan ik. Ik ben er trots op dat jullie beiden aan mijn zijde staan 
vandaag. 
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Dankwoord
Beste ome Jos. Je zult je misschien afvragen wat jouw naam hier doet. Je bent weliswaar 
mijn peetoom maar dat heeft niet zoveel met het proefschrift te maken. Omdat jij diabetes 
hebt werd ik al voordat ik geneeskunde ging studeren geconfronteerd met de impact van de 
ziekte. Ik zag wat het met jouw leven doet en hoeveel energie het jou en Ank heeft gekost om 
er mee om te gaan. Het kan haast niet anders dan dat jij er onbewust voor hebt gezorgd dat 
ik nu doe wat ik doe.  
Lieve (schoon)familie, lieve pap en mam. Jullie wisten natuurlijk dat ik bezig was met een 
promotie maar ik denk niet dat jullie echt wisten wat dit betekent. In onze familie wordt er 
niet zoveel gestudeerd op de universiteit laat staan gepromoveerd. Daarbij was ik er zelf ook 
niet altijd duidelijk over omdat het allemaal zo lang duurde. Kortom, een onderwerp waar ik 
vaak korte antwoorden over gaf. Toch weet ik zeker dat jullie nooit getwijfeld hebben of het 
mij zou lukken, zoals jullie nooit aan mij hebben getwijfeld. Jullie zeggen nog regelmatig dat 
mijn kleuterjuf gezegd heeft dat ik later professor zou worden. Dat zal ik waarschijnlijk niet 
worden maar ik ben nu toch wel in de buurt gekomen. Dit was onmogelijk geweest zonder 
jullie steun. Zowel in morele zin maar zeker ook omdat jullie er altijd voor ons en de kinderen 
zijn. Oppassen, logeren, de tuin doen, de was doen, koken. Zitten we vast, we hoeven maar 
te bellen en dat geldt ook voor mijn schoonouders. We kunnen dit onmogelijk ‘terugbetalen’. 
Ik hoop dat wij, maar vooral ook onze kinderen nog heel lang mogen genieten van hun opa’s 
en oma’s. 
Lieve Douwe en Koen, jullie zijn nog te jong om het helemaal mee te maken vandaag al weet 
ik zeker dat Douwe het al heel interessant zou vinden. Jullie komst maakte jullie meteen de 
nummer 1 prioriteit in mijn leven (sorry Marjo). Alvast een tip voor later als jullie groot zijn: 
promoveer eerst als je dat wil, en krijg dan kinderen. Ik kan me niet voorstellen hoe een leven 
zonder jullie er uit zou zien. Er gaat niks boven een lazy sunday; met zijn vieren in bed met 
cappuccino en chocomel. Ik hoop dat jullie je nog heel lang laten knuffelen. 
Liefste Marjo. Wat moet ik zeggen? het is af! ‘Don’t mention the promotie’ zul je vaak hebben 
gedacht. Een bijna standaard tekst in proefschriften is dat de promovendus eindelijk weer 
tijd krijgt voor zijn gezin. Ik weet niet of dit ook voor mij geldt. Ik denk dat het ons gelukt is de 
afgelopen jaren veel energie in ‘ons’ te steken. Het lukte mij juist maar erg moeizaam om te 
focussen en vrije tijd te besteden aan het proefschrift. Er was trouwens altijd wel een andere 
klus met een strakkere deadline: auditrapport, poli voorbereiden, tentamenvragen maken 
enz. Dat zal niet snel veranderen nu dit af is. Toch spendeerde ik meerdere vakanties aan dit 
proefschrift terwijl jij met de jongens bij het zwembad zat. Dankzij jou ben ik wie ik ben. Wij 
verbazen ons erover dat we zulke knappe kinderen op de wereld hebben gezet. Laten we ons 
nog vaak en tot in lengte van jaren verbazen. Ik hou van je.
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